WO2022071417A1 - フラビン依存性乳酸デヒドロゲナーゼを含む組成物の安定性を向上する方法 - Google Patents
フラビン依存性乳酸デヒドロゲナーゼを含む組成物の安定性を向上する方法 Download PDFInfo
- Publication number
- WO2022071417A1 WO2022071417A1 PCT/JP2021/035929 JP2021035929W WO2022071417A1 WO 2022071417 A1 WO2022071417 A1 WO 2022071417A1 JP 2021035929 W JP2021035929 W JP 2021035929W WO 2022071417 A1 WO2022071417 A1 WO 2022071417A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- ldh
- genus
- group
- lactate dehydrogenase
- Prior art date
Links
- 102000003855 L-lactate dehydrogenase Human genes 0.000 title claims abstract description 353
- 108700023483 L-lactate dehydrogenases Proteins 0.000 title claims abstract description 353
- 239000000203 mixture Substances 0.000 title claims abstract description 93
- 238000000034 method Methods 0.000 title claims abstract description 92
- 230000001419 dependent effect Effects 0.000 title abstract description 10
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 title abstract description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 166
- 239000004310 lactic acid Substances 0.000 claims abstract description 81
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 81
- 239000002253 acid Substances 0.000 claims abstract description 50
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 36
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims abstract description 36
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 150000000000 tetracarboxylic acids Chemical class 0.000 claims abstract description 21
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 18
- 150000001450 anions Chemical class 0.000 claims abstract description 18
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 18
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 18
- 239000000446 fuel Substances 0.000 claims abstract description 17
- 229920000831 ionic polymer Polymers 0.000 claims abstract description 16
- 229920000642 polymer Polymers 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 150000003628 tricarboxylic acids Chemical class 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims description 136
- 150000001875 compounds Chemical class 0.000 claims description 108
- 239000003381 stabilizer Substances 0.000 claims description 91
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 54
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 41
- 150000001413 amino acids Chemical group 0.000 claims description 32
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 28
- 235000011090 malic acid Nutrition 0.000 claims description 28
- 101710088194 Dehydrogenase Proteins 0.000 claims description 25
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 20
- -1 flavin compound Chemical class 0.000 claims description 20
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 claims description 20
- 229920001223 polyethylene glycol Polymers 0.000 claims description 19
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 18
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 18
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 18
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 18
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 18
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 108010039918 Polylysine Proteins 0.000 claims description 17
- 229920000656 polylysine Polymers 0.000 claims description 17
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 16
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 15
- 229920006317 cationic polymer Polymers 0.000 claims description 15
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 14
- 229920002873 Polyethylenimine Polymers 0.000 claims description 14
- 229920002125 Sokalan® Polymers 0.000 claims description 14
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 14
- 229920006318 anionic polymer Polymers 0.000 claims description 14
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 14
- 239000001630 malic acid Substances 0.000 claims description 14
- 239000004584 polyacrylic acid Substances 0.000 claims description 14
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 13
- VOXXWSYKYCBWHO-UHFFFAOYSA-N 3-phenyllactic acid Chemical compound OC(=O)C(O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-UHFFFAOYSA-N 0.000 claims description 12
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 12
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 claims description 12
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 12
- QMKYBPDZANOJGF-UHFFFAOYSA-N benzene-1,3,5-tricarboxylic acid Chemical compound OC(=O)C1=CC(C(O)=O)=CC(C(O)=O)=C1 QMKYBPDZANOJGF-UHFFFAOYSA-N 0.000 claims description 12
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 claims description 12
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims description 12
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 12
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 11
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 11
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 11
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 10
- 239000004471 Glycine Substances 0.000 claims description 10
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 10
- 239000004472 Lysine Substances 0.000 claims description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 claims description 10
- KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 claims description 10
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 9
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- 235000003704 aspartic acid Nutrition 0.000 claims description 9
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 9
- 235000013922 glutamic acid Nutrition 0.000 claims description 9
- 239000004220 glutamic acid Substances 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 9
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 239000005515 coenzyme Substances 0.000 claims description 8
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 8
- 235000021317 phosphate Nutrition 0.000 claims description 8
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 claims description 8
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 7
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 7
- 241000235070 Saccharomyces Species 0.000 claims description 7
- 229930006000 Sucrose Natural products 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 7
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 7
- 239000001530 fumaric acid Substances 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 230000002779 inactivation Effects 0.000 claims description 7
- 229960000367 inositol Drugs 0.000 claims description 7
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 7
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 7
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 7
- 239000011975 tartaric acid Substances 0.000 claims description 7
- 235000002906 tartaric acid Nutrition 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 6
- XVOUMQNXTGKGMA-OWOJBTEDSA-N (E)-glutaconic acid Chemical compound OC(=O)C\C=C\C(O)=O XVOUMQNXTGKGMA-OWOJBTEDSA-N 0.000 claims description 6
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 6
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 claims description 6
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 6
- 241001112159 Ogataea Species 0.000 claims description 6
- YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 6
- 229940091181 aconitic acid Drugs 0.000 claims description 6
- 239000001361 adipic acid Substances 0.000 claims description 6
- 235000011037 adipic acid Nutrition 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 6
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 claims description 6
- HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 claims description 6
- 229940018557 citraconic acid Drugs 0.000 claims description 6
- 150000001991 dicarboxylic acids Chemical class 0.000 claims description 6
- 239000000174 gluconic acid Substances 0.000 claims description 6
- 235000012208 gluconic acid Nutrition 0.000 claims description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 6
- 239000011976 maleic acid Substances 0.000 claims description 6
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 claims description 6
- 235000006408 oxalic acid Nutrition 0.000 claims description 6
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims description 6
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 claims description 6
- BTUDGPVTCYNYLK-UHFFFAOYSA-N 2,2-dimethylglutaric acid Chemical compound OC(=O)C(C)(C)CCC(O)=O BTUDGPVTCYNYLK-UHFFFAOYSA-N 0.000 claims description 5
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 claims description 5
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 claims description 5
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 claims description 5
- ZEGRKMXCOCRTCS-UHFFFAOYSA-N Poppy acid Chemical compound OC(=O)C1=CC(=O)C(O)=C(C(O)=O)O1 ZEGRKMXCOCRTCS-UHFFFAOYSA-N 0.000 claims description 5
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 claims description 5
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 claims description 5
- LIVNCPMCQTZXRZ-UHFFFAOYSA-N meconic acid Natural products CC(=O)C1=CC(=O)C(O)=C(C(C)=O)O1 LIVNCPMCQTZXRZ-UHFFFAOYSA-N 0.000 claims description 5
- HNEGQIOMVPPMNR-NSCUHMNNSA-N mesaconic acid Chemical compound OC(=O)C(/C)=C/C(O)=O HNEGQIOMVPPMNR-NSCUHMNNSA-N 0.000 claims description 5
- HNEGQIOMVPPMNR-UHFFFAOYSA-N methylfumaric acid Natural products OC(=O)C(C)=CC(O)=O HNEGQIOMVPPMNR-UHFFFAOYSA-N 0.000 claims description 5
- ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 claims description 5
- VQTLPSCRBFYDNX-PIKHSQJKSA-N (2s)-2,4-diamino-3-hydroxy-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C(N)=O VQTLPSCRBFYDNX-PIKHSQJKSA-N 0.000 claims description 4
- 108020005199 Dehydrogenases Proteins 0.000 claims description 4
- 241001149669 Hanseniaspora Species 0.000 claims description 4
- 241001444195 Madurella Species 0.000 claims description 4
- 235000011180 diphosphates Nutrition 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 41
- 238000005259 measurement Methods 0.000 abstract description 38
- 238000003860 storage Methods 0.000 abstract description 16
- 238000003149 assay kit Methods 0.000 abstract description 10
- 230000009849 deactivation Effects 0.000 abstract description 3
- 150000002763 monocarboxylic acids Chemical class 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 90
- 125000003275 alpha amino acid group Chemical group 0.000 description 67
- 229960000448 lactic acid Drugs 0.000 description 67
- 229940001447 lactate Drugs 0.000 description 53
- 102000004190 Enzymes Human genes 0.000 description 44
- 108090000790 Enzymes Proteins 0.000 description 44
- 229940088598 enzyme Drugs 0.000 description 44
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 42
- 235000001014 amino acid Nutrition 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- 238000010438 heat treatment Methods 0.000 description 27
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 25
- 229940098773 bovine serum albumin Drugs 0.000 description 25
- 239000008057 potassium phosphate buffer Substances 0.000 description 25
- 230000003287 optical effect Effects 0.000 description 22
- 108090000623 proteins and genes Proteins 0.000 description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 21
- 229940024606 amino acid Drugs 0.000 description 20
- 244000005700 microbiome Species 0.000 description 20
- 238000012360 testing method Methods 0.000 description 17
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 16
- 239000000126 substance Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- 229960002885 histidine Drugs 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- CCBICDLNWJRFPO-UHFFFAOYSA-N 2,6-dichloroindophenol Chemical compound C1=CC(O)=CC=C1N=C1C=C(Cl)C(=O)C(Cl)=C1 CCBICDLNWJRFPO-UHFFFAOYSA-N 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 229910052799 carbon Inorganic materials 0.000 description 12
- 230000006872 improvement Effects 0.000 description 12
- 229940116298 l- malic acid Drugs 0.000 description 12
- 229940099690 malic acid Drugs 0.000 description 12
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 12
- 238000012795 verification Methods 0.000 description 12
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 11
- 101000641031 Homo sapiens Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Proteins 0.000 description 11
- 102000018832 Cytochromes Human genes 0.000 description 10
- 108010052832 Cytochromes Proteins 0.000 description 10
- 229960002989 glutamic acid Drugs 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 150000003627 tricarboxylic acid derivatives Chemical class 0.000 description 10
- 238000002835 absorbance Methods 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 235000014304 histidine Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 230000000087 stabilizing effect Effects 0.000 description 9
- 102000004316 Oxidoreductases Human genes 0.000 description 8
- 108090000854 Oxidoreductases Proteins 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 229960000723 ampicillin Drugs 0.000 description 8
- 235000009697 arginine Nutrition 0.000 description 8
- 229960003121 arginine Drugs 0.000 description 8
- 229960005261 aspartic acid Drugs 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 229960003646 lysine Drugs 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 229960003136 leucine Drugs 0.000 description 7
- 235000018977 lysine Nutrition 0.000 description 7
- 229910052697 platinum Inorganic materials 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- NGSFWBMYFKHRBD-DKWTVANSSA-M sodium;(2s)-2-hydroxypropanoate Chemical compound [Na+].C[C@H](O)C([O-])=O NGSFWBMYFKHRBD-DKWTVANSSA-M 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- YYLQUHNPNCGKJQ-PIKHSQJKSA-N 3-hydroxy-L-aspartic acid Chemical compound OC(=O)[C@@H](N)C(O)C(O)=O YYLQUHNPNCGKJQ-PIKHSQJKSA-N 0.000 description 5
- 241000672609 Escherichia coli BL21 Species 0.000 description 5
- 241000235648 Pichia Species 0.000 description 5
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000007800 oxidant agent Substances 0.000 description 5
- 229910000160 potassium phosphate Inorganic materials 0.000 description 5
- 235000011009 potassium phosphates Nutrition 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- PRWXGRGLHYDWPS-UHFFFAOYSA-L sodium malonate Chemical compound [Na+].[Na+].[O-]C(=O)CC([O-])=O PRWXGRGLHYDWPS-UHFFFAOYSA-L 0.000 description 5
- LKIUUVZMMOKAMF-UHFFFAOYSA-N 2-(2,6-difluorophenyl)-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)C1=C(F)C=CC=C1F LKIUUVZMMOKAMF-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 241000221955 Chaetomium Species 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 4
- 241000235017 Zygosaccharomyces Species 0.000 description 4
- 125000000129 anionic group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 238000000970 chrono-amperometry Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 229960002449 glycine Drugs 0.000 description 4
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 4
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- IIPYXGDZVMZOAP-UHFFFAOYSA-N lithium nitrate Chemical compound [Li+].[O-][N+]([O-])=O IIPYXGDZVMZOAP-UHFFFAOYSA-N 0.000 description 4
- YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Chemical compound [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 4
- 229960002160 maltose Drugs 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 4
- 229940005642 polystyrene sulfonic acid Drugs 0.000 description 4
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000027756 respiratory electron transport chain Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 4
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 4
- 229940074410 trehalose Drugs 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- HBDJFVFTHLOSDW-DNDLZOGFSA-N (2r,3r,4r,5r)-2,3,5,6-tetrahydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal;hydrate Chemical compound O.O=C[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HBDJFVFTHLOSDW-DNDLZOGFSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241001494491 Chaetomiaceae Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 239000001358 L(+)-tartaric acid Substances 0.000 description 3
- 235000011002 L(+)-tartaric acid Nutrition 0.000 description 3
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 3
- 241000235645 Pichia kudriavzevii Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229910002804 graphite Inorganic materials 0.000 description 3
- 239000010439 graphite Substances 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- 150000002366 halogen compounds Chemical class 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- AUONNNVJUCSETH-UHFFFAOYSA-N icosanoyl icosanoate Chemical compound CCCCCCCCCCCCCCCCCCCC(=O)OC(=O)CCCCCCCCCCCCCCCCCCC AUONNNVJUCSETH-UHFFFAOYSA-N 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 229960003017 maltose monohydrate Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 150000002823 nitrates Chemical class 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000010248 power generation Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- SXJCWCGNPYHALZ-UHFFFAOYSA-N propanedioic acid;sodium Chemical compound [Na].[Na].OC(=O)CC(O)=O SXJCWCGNPYHALZ-UHFFFAOYSA-N 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 238000012036 ultra high throughput screening Methods 0.000 description 3
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UWTATZPHSA-N (R)-malic acid Chemical compound OC(=O)[C@H](O)CC(O)=O BJEPYKJPYRNKOW-UWTATZPHSA-N 0.000 description 2
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 2
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 239000004254 Ammonium phosphate Substances 0.000 description 2
- 241000235349 Ascomycota Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000722885 Brettanomyces Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241001563619 Ogataea parapolymorpha Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229910001260 Pt alloy Inorganic materials 0.000 description 2
- 241000235343 Saccharomycetales Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 241000221926 Sordariales Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 2
- 235000019289 ammonium phosphates Nutrition 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 238000004082 amperometric method Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 239000006229 carbon black Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XMXOIHIZTOVVFB-JIZZDEOASA-L disodium;(2s)-2-aminobutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CC([O-])=O XMXOIHIZTOVVFB-JIZZDEOASA-L 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000002848 electrochemical method Methods 0.000 description 2
- 229940021013 electrolyte solution Drugs 0.000 description 2
- 239000008151 electrolyte solution Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000012407 engineering method Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000002828 fuel tank Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- ROBFUDYVXSDBQM-UHFFFAOYSA-N hydroxymalonic acid Chemical compound OC(=O)C(O)C(O)=O ROBFUDYVXSDBQM-UHFFFAOYSA-N 0.000 description 2
- 239000003014 ion exchange membrane Substances 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229910001386 lithium phosphate Inorganic materials 0.000 description 2
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 2
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 2
- 239000004137 magnesium phosphate Substances 0.000 description 2
- 229960002261 magnesium phosphate Drugs 0.000 description 2
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 2
- 235000010994 magnesium phosphates Nutrition 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 150000004986 phenylenediamines Chemical class 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000004323 potassium nitrate Substances 0.000 description 2
- 235000010333 potassium nitrate Nutrition 0.000 description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 description 2
- 235000011151 potassium sulphates Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 229940107700 pyruvic acid Drugs 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- 235000012207 sodium gluconate Nutrition 0.000 description 2
- 239000000176 sodium gluconate Substances 0.000 description 2
- 229940005574 sodium gluconate Drugs 0.000 description 2
- 239000004317 sodium nitrate Substances 0.000 description 2
- 235000010344 sodium nitrate Nutrition 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000006076 specific stabilizer Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- TWQULNDIKKJZPH-UHFFFAOYSA-K trilithium;phosphate Chemical compound [Li+].[Li+].[Li+].[O-]P([O-])([O-])=O TWQULNDIKKJZPH-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 1
- YYLQUHNPNCGKJQ-LWMBPPNESA-N (3S)-3-hydroxy-L-aspartic acid Chemical compound OC(=O)[C@@H](N)[C@H](O)C(O)=O YYLQUHNPNCGKJQ-LWMBPPNESA-N 0.000 description 1
- VOXXWSYKYCBWHO-QMMMGPOBSA-N (S)-3-phenyllactic acid Chemical compound OC(=O)[C@@H](O)CC1=CC=CC=C1 VOXXWSYKYCBWHO-QMMMGPOBSA-N 0.000 description 1
- CBCKQZAAMUWICA-UHFFFAOYSA-N 1,4-phenylenediamine Chemical compound NC1=CC=C(N)C=C1 CBCKQZAAMUWICA-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- LVRFTAZAXQPQHI-UHFFFAOYSA-N 2-hydroxy-4-methylvaleric acid Chemical compound CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LUAZZOXZPVVGSO-UHFFFAOYSA-N Benzyl viologen Chemical compound C=1C=C(C=2C=C[N+](CC=3C=CC=CC=3)=CC=2)C=C[N+]=1CC1=CC=CC=C1 LUAZZOXZPVVGSO-UHFFFAOYSA-N 0.000 description 1
- 108010015428 Bilirubin oxidase Proteins 0.000 description 1
- 244000027711 Brettanomyces bruxellensis Species 0.000 description 1
- 235000000287 Brettanomyces bruxellensis Nutrition 0.000 description 1
- 241000722860 Brettanomyces naardenensis Species 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000048017 Cyberlindnera Species 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 238000012218 Kunkel's method Methods 0.000 description 1
- 241001304302 Kuraishia capsulata Species 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 108010029541 Laccase Proteins 0.000 description 1
- 241000858110 Lachancea Species 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- FBWADIKARMIWNM-UHFFFAOYSA-N N-3,5-dichloro-4-hydroxyphenyl-1,4-benzoquinone imine Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1N=C1C=CC(=O)C=C1 FBWADIKARMIWNM-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- OUBMGJOQLXMSNT-UHFFFAOYSA-N N-isopropyl-N'-phenyl-p-phenylenediamine Chemical compound C1=CC(NC(C)C)=CC=C1NC1=CC=CC=C1 OUBMGJOQLXMSNT-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 241000486797 Naumovozyma Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000336025 Ogataea parapolymorpha DL-1 Species 0.000 description 1
- 241001099341 Ogataea polymorpha Species 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 241000235062 Pichia membranifaciens Species 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 241001123228 Saccharomyces paradoxus Species 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 241001326533 Sordariomycetes Species 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 241000235006 Torulaspora Species 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 241000222124 [Candida] boidinii Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 229940044197 ammonium sulfate Drugs 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000002819 bacterial display Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000013622 capto Q Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 239000003575 carbonaceous material Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000003869 coulometry Methods 0.000 description 1
- 238000002484 cyclic voltammetry Methods 0.000 description 1
- PORCMJJTZXANLJ-UHFFFAOYSA-N cyclopenta-1,3-diene iron(2+) Chemical class [Fe++].[Fe++].c1cc[cH-]c1.c1cc[cH-]c1.c1cc[cH-]c1.c1cc[cH-]c1 PORCMJJTZXANLJ-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007357 dehydrogenase reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 238000001903 differential pulse voltammetry Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000003411 electrode reaction Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 125000004072 flavinyl group Chemical group 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229910021397 glassy carbon Inorganic materials 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910021389 graphene Inorganic materials 0.000 description 1
- 238000007646 gravure printing Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- UACSZOWTRIJIFU-UHFFFAOYSA-N hydroxymethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCO UACSZOWTRIJIFU-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- RSAZYXZUJROYKR-UHFFFAOYSA-N indophenol Chemical class C1=CC(O)=CC=C1N=C1C=CC(=O)C=C1 RSAZYXZUJROYKR-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- KYMNSBSWJPFUJH-UHFFFAOYSA-N iron;5-methylcyclopenta-1,3-diene;methylcyclopentane Chemical compound [Fe].C[C-]1C=CC=C1.C[C-]1[CH-][CH-][CH-][CH-]1 KYMNSBSWJPFUJH-UHFFFAOYSA-N 0.000 description 1
- 239000003273 ketjen black Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 101150104734 ldh gene Proteins 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000011147 magnesium chloride Nutrition 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 229950006238 nadide Drugs 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000002907 osmium Chemical class 0.000 description 1
- LOGFOEGYMPSLHL-UHFFFAOYSA-N osmium;2-pyridin-2-ylpyridine Chemical compound [Os].N1=CC=CC=C1C1=CC=CC=N1 LOGFOEGYMPSLHL-UHFFFAOYSA-N 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000002988 phenazines Chemical class 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000001524 potential step chrono-amperometry Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 241000137058 saccharomyceta Species 0.000 description 1
- 238000002804 saturated mutagenesis Methods 0.000 description 1
- 238000007650 screen-printing Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000002174 soft lithography Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000037078 sports performance Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229940074409 trehalose dihydrate Drugs 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000004832 voltammetry Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
- C12Q1/005—Enzyme electrodes involving specific analytes or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/02—Oxidoreductases acting on the CH-OH group of donors (1.1) with a cytochrome as acceptor (1.1.2)
- C12Y101/02003—L-Lactate dehydrogenase (cytochrome) (1.1.2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01027—L-Lactate dehydrogenase (1.1.1.27)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01028—D-Lactate dehydrogenase (1.1.1.28)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
Definitions
- the present disclosure relates to a method for improving the stability of a composition containing a flavin-dependent dehydrogenase and a composition obtained by using the method.
- Lactate concentration and sweat lactate concentration are known as markers that reflect fatigue and physical condition. Lactic acid is a major metabolite and is recognized to be important not only for health management indicators but also for health assessments including serious illness and / or surgical patients, and lactate levels in body fluids are circulatory insufficiency, liver. It can be an index for various pathological conditions such as disorders. Lactate monitoring can be used to detect sepsis, hypoxia, and the presence of cancerous tissue (Non-Patent Document 1).
- Non-Patent Document 2 For the purpose of physical condition management not limited to sick people, lactate monitoring is performed as an index for monitoring the appropriateness of training conducted by athletes and those who are highly interested in exercising on a daily basis.
- LDH flavin-dependent lactate dehydrogenase
- Non-Patent Document 3 describes that LDH derived from Saccharomyces cerevisiae known so far has a problem in stability.
- lactate dehydrogenase nicotinamide adenine dinucleotide-dependent lactate dehydrogenase is also known, but it is not included in flavin-dependent lactate dehydrogenase (LDH). Therefore, in the present specification, the term flavin-dependent lactate dehydrogenase, or LDH, does not include nicotinamide-dependent lactate dehydrogenase unless otherwise specified.
- the present disclosures have found that the stability of LDH is improved by coexisting various compounds in a composition containing LDH, and further, electrodes. It has been found that the inactivation of LDH applied to can be suppressed, and the present disclosure including these embodiments has been completed.
- the present disclosure provides the following embodiments.
- a method for improving the thermal stability of a lactic acid dehydrogenase-containing composition which comprises the step of allowing one or more kinds of anions, monosaccharides, disaccharides, polyethylene glycols, or ionic polymers selected from the group to coexist.
- Lactic dehydrogenases are genus Saccharomyces, genus Pikia, genus Candida, genus Ogataea, genus Bretanomyces, genus Cibellindonella, genus Hansenia spora, genus Kazatutania, genus Kruiwelomyces, genus Lachansea, genus Naumovodima, genus Tetrapicispora. The method according to 1.
- Lactate dehydrogenase having an amino acid sequence having an amino acid sequence of 70% or more or 80% or more identity with the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, or SEQ ID NO: 10.
- SEQ ID NO: 4 138 to 140, 186 to 194, 217 to 222, 243 to 245, 271 to 278, 280 to 283, 355 to 367, 398 to 401, 403 to 403.
- Lactate dehydrogenase having 80% or more or 90% or more sequence identity between the amino acid sequence in the homology region consisting of the amino acid sequences at positions 406 and 425 to 433 and the amino acid sequence in the homology region at the corresponding position of the lactate dehydrogenase. .. [4]
- the monocarboxylic acid is selected from the group consisting of gluconic acid, leucine acid, 3-phenyllactic acid, glycine, lysine, histidine and arginine.
- Dicarboxylic acids are malic acid, succinic acid, maleic acid, fumaric acid, malonic acid, methylmalonic acid, oxaloacetic acid, tartaric acid, oxalic acid, succinic acid, glutaric acid, ⁇ -ketoglutaric acid, adipic acid, pimelic acid, sveric acid, Azelaic acid, sebasic acid, phthalic acid, isophthalic acid, terephthalic acid, glutaconic acid, tarthronic acid, muconic acid, mesaconic acid, citraconic acid, meconic acid, 3-3'dimethylglutaric acid, itaconic acid, glutamic acid, aspartic acid, and Selected from the group consisting of 3-hydroxyasparagine,
- the tricarboxylic acid is selected from the group consisting of citric acid, isocitric acid, aconitic acid, trimesic acid, 1,2,3-propanetricarboxylic acid
- Tetracarboxylic acid is selected from ethylenediaminetetraacetic acid
- Phosphoric acid is selected from the group consisting of phosphates and pyrophosphates.
- Sulfuric acid is selected from sulfates
- Monosaccharides are selected from the group consisting of myo-inositol
- the disaccharide is selected from the group consisting of sucrose, trehalose, and maltose, or polyethylene glycol
- the ionic polymer is an anionic polymer or a cationic polymer
- the anionic polymer is selected from the group consisting of polyacrylic acid, hyaluronic acid, and carboxymethyl cellulose or salts thereof, or
- the method for improving the thermal stability of the lactate dehydrogenase-containing composition according to any one of 1 to 3, wherein the cationic polymer is selected from polylysine, polyethyleneimine, methylglycolchitosan, and poly (diallyldimethylammoni
- lactic acid dehydrogenase having a flavine compound as a coenzyme monocarboxylic acid, dicarboxylic acid, tricarboxylic acid, tetracarboxylic acid, polycarboxylic acid, phosphoric acid, sulfuric acid or salts thereof (excluding ammonium sulfate).
- a composition for measuring lactic acid which comprises one or more compounds of anion, monosaccharide, disaccharide, polyethylene glycol, and ionic polymer.
- Lactic dehydrogenases are genus Saccharomyces, genus Pikia, genus Candida, genus Ogataea, genus Bretanomyces, genus Cibellindonella, genus Hansenia spora, genus Kazatutania, genus Kluywellomyces, genus Lachansea, genus Naumovodima, genus Tetrapicispora, 6.
- composition for measuring lactic acid according to 6, which is a lactic acid dehydrogenase derived from the genus Van der Waldjima, the genus Zigosaccharomyces, the genus Zigotorlapora, the genus Misserioftra, the genus Thermocellomyces, the genus Caetomium, or the genus Madurella.
- lactate dehydrogenase is (i) and / or (ii) below.
- Lactate dehydrogenase having an amino acid sequence having an amino acid sequence of 70% or more or 80% or more identity with the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 7, or SEQ ID NO: 10.
- SEQ ID NO: 4 138 to 140, 186 to 194, 217 to 222, 243 to 245, 271 to 278, 280 to 283, 355 to 367, 398 to 401, 403 to 403.
- Lactate dehydrogenase having 80% or more or 90% or more sequence identity between the amino acid sequence in the homology region consisting of the amino acid sequences at positions 406 and 425 to 433 and the amino acid sequence in the homology region at the corresponding position of the lactate dehydrogenase. .. [9]
- the monocarboxylic acid is selected from the group consisting of gluconic acid, leucine acid, 3-phenyllactic acid, glycine, lysine, histidine and arginine.
- Dicarboxylic acids are malic acid, succinic acid, maleic acid, fumaric acid, malonic acid, methylmalonic acid, oxaloacetic acid, tartaric acid, oxalic acid, succinic acid, glutaric acid, ⁇ -ketoglutaric acid, adipic acid, pimelic acid, sveric acid, Azelaic acid, sebasic acid, phthalic acid, isophthalic acid, terephthalic acid, glutaconic acid, tarthronic acid, muconic acid, mesaconic acid, citraconic acid, meconic acid, 3-3'dimethylglutaric acid, itaconic acid, glutamic acid, aspartic acid, and Selected from the group consisting of 3-hydroxyasparagine,
- the tricarboxylic acid is selected from the group consisting of citric acid, isocitric acid, aconitic acid, trimesic acid, 1,2,3-propanetricarboxylic acid
- Tetracarboxylic acid is selected from ethylenediaminetetraacetic acid
- Phosphoric acid is selected from the group consisting of phosphates and pyrophosphates.
- Sulfuric acid is selected from sulfates
- Monosaccharides are selected from the group consisting of myo-inositol
- the disaccharide is selected from the group consisting of sucrose, trehalose, and maltose, or polyethylene glycol
- the ionic polymer is an anionic polymer or a cationic polymer
- Anionic polymers are selected from the group consisting of polyacrylic acid, hyaluronic acid, and carboxymethyl cellulose or salts thereof. 6.
- composition for measuring lactic acid according to any one of 6 to 8, wherein the cationic polymer is selected from polylysine, polyethyleneimine, methylglycolchitosan, and poly (diallyldimethylammonium chloride).
- An electrode containing a composition containing one or more compounds of sugar, disaccharide, polyethylene glycol, and an ionic polymer [13] A lactate sensor comprising the electrode according to 12. [14] A fuel cell comprising the electrode according to 12. [15] A method for suppressing a decrease in activity or inactivation of lactate dehydrogenase in a method for producing an electrode, which comprises a step of applying lactate dehydrogenase to the electrode.
- Steps to prepare a solution containing lactate dehydrogenase i) Steps to prepare a solution containing lactate dehydrogenase, ii) An anion, monosaccharide, disaccharide, polyethylene glycol selected from the group consisting of monocarboxylic acid, dicarboxylic acid, tricarboxylic acid, tetracarboxylic acid, polycarboxylic acid, phosphoric acid, sulfuric acid or salts thereof in the solution.
- a step of adding one or more stabilizers selected from the group consisting of ionic polymers iii)
- a step of applying a solution containing the lactate dehydrogenase and the stabilizer to the electrode iv) The step of drying the applied solution, The method described above. [16] The production method according to 15, wherein the electrode coated with lactate dehydrogenase is included in the lactate sensor.
- the present disclosure is characterized in that the thermal stability of the LDH-containing composition can be improved by coexisting any additive component with any LDH. Attempts to modify LDH itself to improve thermal stability are not known, and an effective thermal stability improver for LDH and LDH-containing compositions having improved thermal stability as a composition are not known. The knowledge was scarce.
- the present disclosure provides a method of improving the stability of a composition comprising LDH. It has been found that anionic or sugar or ionic polymers are effective as compounds added to improve the stability of the composition containing LDH of the present disclosure. That is, the present disclosure provides, in certain embodiments, stabilizers that improve the stability of compositions containing LDH. Stabilizers that enhance the stability of compositions containing LDH may include anionic, sugar, and / or ionic (cationic, anionic, zwitterionic) polymers.
- the anion of the present disclosure is not particularly limited as long as it improves the thermal stability of the LDH-containing composition of the present disclosure, and is, for example, a carboxyl group-containing compound, a halogen compound, a phosphate, a nitrate, a sulfate, or a protein. , Peptides, amino acids and the like.
- the carboxyl group-containing compound include, but are not limited to, monocarboxylic acid, dicarboxylic acid, tricarboxylic acid, tetracarboxylic acid, and polycarboxylic acid compound.
- preferred anions used in the present invention are, but are not limited to, one or more dicarboxylic acids or tricarboxylic acids, tetracarboxylic acids, polycarboxylic acids or salts thereof.
- a nonionic polymer polyethylene glycol may be used.
- the ionic polymer may be a cationic polymer, an anionic polymer or a zwitterionic polymer. Examples of the cationic polymer include, but are not limited to, polylysine, polyethyleneimine, methylglycolchitosan, poly (diallyldimethylammonium chloride) and the like.
- anionic polymer examples include hyaluronic acid, a cellulose derivative (for example, carboxymethyl cellulose), a polyacrylic acid derivative (for example, polyacrylic acid), a polymethacrylic acid derivative (for example, polymethylmethacrylate and hydroxymethylmethacrylate) and the like.
- a cellulose derivative for example, carboxymethyl cellulose
- a polyacrylic acid derivative for example, polyacrylic acid
- a polymethacrylic acid derivative for example, polymethylmethacrylate and hydroxymethylmethacrylate
- the zwitterionic polymer examples include, but are not limited to, the poly (carboxybetaine methacrylate) described in JP-A-2017-527669.
- compounds added to improve the stability of a composition containing LDH may be referred to as LDH stabilizers, or simply stabilizers. However, this does not prevent the LDH stabilizer from containing other compounds.
- the stabilizer added to improve the stability of the composition containing LDH comprises a compound that stabilizes LDH.
- the stabilizer may contain other compounds.
- ammonium sulphate in particular 50% by weight or more, is removed from the sulphate.
- the monocarboxylic acid used in the present disclosure is not particularly limited as long as it improves the stability of the composition containing LDH of the present disclosure, and is, for example, gluconic acid, leucic acid, 3-phenyllactic acid. , Glycine, arginine, lysine, histidine are exemplified as preferred monocarboxylic acids. In certain embodiments, the monocarboxylic acid used in the present disclosure may have 7 or less carbon atoms in the backbone.
- preferred dicarboxylic acids used in the present disclosure include malic acid, succinic acid, maleic acid, fumaric acid, malonic acid, methylmalonic acid, oxaloacetate, tartrate acid, oxalic acid, succinic acid, glutaric acid, ⁇ -.
- glutaric acid, itaconic acid, glutamic acid, aspartic acid, 3-hydroxyaspartic acid and the like examples thereof include glutaric acid, itaconic acid, glutamic acid, aspartic acid, 3-hydroxyaspartic acid and the like.
- preferred tricarboxylic acids used in the present disclosure include citric acid, isocitric acid, aconitic acid, trimesic acid, 1,2,3-propanetricarboxylic acid, 2-phosphonobutane-1,2,4-tricarboxylic acid and the like. Can be mentioned.
- preferred tetracarboxylic acids used in the present disclosure include ethylenediaminetetraacetic acid (EDTA) and the like.
- the preferred sugar used in the present disclosure is not particularly limited as long as it improves the stability of the composition containing LDH of the present disclosure, such as monosaccharide, disaccharide, oligosaccharide, and is not particularly limited, but for example, sucrose. , Trehalose, maltose, myo-inositol and the like.
- the molecular weight of the polyethylene glycol preferably used in the present disclosure is not particularly limited, but for example, an average molecular weight of 300 to 100,000 is preferable, and 7,300 to 9,300 is particularly preferable.
- preferred cationic polymers used in the present disclosure include, for example, polylysine, polyethyleneimine, methylglycolchitosan, and poly (diallyldimethylammonium chloride), and polylysine includes ⁇ -polylysine or ⁇ -polylysine. Be done.
- the molecular weight of polylysine is not particularly limited, but for example, polylysine having an average molecular weight of 300 to 100,000 is preferable, and further 3,500 to 6,000, for example 3,000 to 5,000, for example 3,500 to 4, Polylysine of 500 is preferred, but not limited to.
- Polyethyleneimine may be linear or branched.
- the molecular weight of polyethyleneimine is not particularly limited, but for example, polyethyleneimine having an average molecular weight of 300 to 100,000, for example, 3000 to 20,000, for example, 3500 to 10,000 can be used.
- preferred anionic polymers used in the present disclosure include polyacrylic acid, polystyrene sulfonic acid, hyaluronic acid or salts thereof, and carboxymethyl cellulose or salts thereof.
- the molecular weight of polyacrylic acid is not particularly limited, but for example, polyacrylic acid having an average molecular weight of 1000 to 1,250,000 is preferable, but not limited to this.
- the molecular weight of polystyrene sulfonic acid is not particularly limited, but for example, polystyrene sulfonic acid having an average molecular weight of 1000 to 1,000,000 is preferable, but not limited to this.
- preferred nitrates used in the present disclosure include sodium nitrate, ammonium nitrate, magnesium nitrate, potassium nitrate, calcium nitrate, lithium nitrate and the like.
- preferred sulfates used in the present disclosure include sodium sulfate, ammonium sulfate, magnesium sulfate, potassium sulfate, calcium sulfate, lithium sulfate and the like.
- preferred phosphates used in the present disclosure include sodium phosphate, ammonium phosphate, magnesium phosphate, potassium phosphate, calcium phosphate, lithium phosphate and the like.
- the preferred anion or sugar used in the present disclosure is one or more carboxyl group-containing compounds, halogen compounds, phosphates, nitrates, sulfates, proteins, peptides, amino acids or salts thereof, or sugars. be.
- gluconic acid in another embodiment, from the stabilizers of the present disclosure, gluconic acid, leucic acid, 3-phenyllactic acid, glycine, arginine, lysine, histidine, malic acid, succinic acid, maleic acid, fumaric acid, malonic acid, methylmalon.
- Acid oxaloacetic acid, tartaric acid, oxalic acid, succinic acid, glutaric acid, ⁇ -ketoglutaric acid, adipic acid, pimelli acid, suberic acid, azelaic acid, sebacic acid, phthalic acid, isophthalic acid, terephthalic acid, glutaconic acid, tartronic acid , Mucon acid, mesacon acid, citraconic acid, mecon acid, 3-3'dimethylglutaric acid, itaconic acid, glutamic acid, aspartic acid, 3-hydroxyaspartic acid, citric acid, isocitrate, aconitic acid, trimesic acid, 1, 2 , 3-Propanitricarboxylic acid, 2-phosphonobutane-1,2,4-tricarboxylic acid, ethylenediaminetetraacetic acid (EDTA), hyaluronic acid or a salt thereof, and carboxymethyl cellulose or a salt thereof, sucrose,
- leucine acid may be provided as L-form and D-form, or a mixture of L-form and D-form, for example, racemic form.
- the L-form for a certain optically active compound means that the L-form is present at, for example, an optical purity of 90 to 100% ee, for example, 95 to 100% ee, for example, 97 to 100% ee.
- L-leucine acid can be of optical purity 90-100% ee, eg 95-100% ee, eg 97-100% ee.
- the racemate is shown in this specification, it is described as DL- before the name of the compound.
- 3-phenyllactic acid may be provided as L-form and D-form, or a mixture of L-form and D-form, for example, racemic form.
- the L-form for a certain optically active compound means that the L-form is present at, for example, an optical purity of 90 to 100% ee, for example, 95 to 100% ee, for example, 97 to 100% ee.
- L-3-phenyllactic acid can have an optical purity of 90-100% ee, eg 95-100% ee, eg 97-100% ee.
- the racemate is shown in this specification, it is described as DL- before the name of a compound.
- arginine may be provided as L-form and D-form, or a mixture of L-form and D-form, for example, racemic form.
- the L-form for a certain optically active compound means that the L-form is present at, for example, an optical purity of 90 to 100% ee, for example, 95 to 100% ee, for example, 97 to 100% ee.
- L-arginine can be of optical purity 90-100% ee, eg 95-100% ee, eg 97-100% ee.
- the racemate is shown in this specification, it is described as DL- before the name of the compound.
- lysine may be provided as L-form and D-form, or a mixture of L-form and D-form, for example, racemic form.
- the L-form for a certain optically active compound means that the L-form is present at, for example, an optical purity of 90 to 100% ee, for example, 95 to 100% ee, for example, 97 to 100% ee.
- L-lysine can have an optical purity of 90-100% ee, such as 95-100% ee, such as 97-100% ee.
- the racemate is shown in this specification, it is described as DL- before the name of the compound.
- histidine may be provided as an L-form and a D-form, or a mixture of the L-form and the D-form, for example, a racemic form.
- the L-form for a certain optically active compound means that the L-form is present at, for example, an optical purity of 90 to 100% ee, for example, 95 to 100% ee, for example, 97 to 100% ee.
- L-histidine can have an optical purity of 90-100% ee, such as 95-100% ee, such as 97-100% ee.
- the racemate is shown in this specification, it is described as DL- before the name of the compound.
- malic acid may be provided as L-form and D-form, or a mixture of L-form and D-form, for example, racemic acid.
- the L-form for a certain optically active compound means that the L-form is present at, for example, an optical purity of 90 to 100% ee, for example, 95 to 100% ee, for example, 97 to 100% ee.
- L-malic acid can be of optical purity 90-100% ee, eg 95-100% ee, eg 97-100% ee.
- the racemate is shown in this specification, it is described as DL- before the name of the compound.
- tartaric acid may be provided as L-form and D-form, or a mixture of L-form and D-form, for example, racemic acid.
- the L-form for a certain optically active compound means that the L-form is present at, for example, an optical purity of 90 to 100% ee, for example, 95 to 100% ee, for example, 97 to 100% ee.
- L-tartaric acid can have an optical purity of 90-100% ee, such as 95-100% ee, such as 97-100% ee.
- the racemate is shown in this specification, it is described as DL- before the name of the compound.
- glutamic acid may be provided as L-form and D-form, or a mixture of L-form and D-form, for example, racemic acid.
- the L-form for a certain optically active compound means that the L-form is present at, for example, an optical purity of 90 to 100% ee, for example, 95 to 100% ee, for example, 97 to 100% ee.
- L-glutamic acid can have an optical purity of 90-100% ee, such as 95-100% ee, such as 97-100% ee.
- the racemate is shown in this specification, it is described as DL- before the name of the compound.
- aspartic acid may be provided as L-form and D-form, or a mixture of L-form and D-form, for example, racemic form.
- the L-form for a certain optically active compound means that the L-form is present at, for example, an optical purity of 90 to 100% ee, for example, 95 to 100% ee, for example, 97 to 100% ee.
- L-aspartic acid can be of optical purity 90-100% ee, eg 95-100% ee, eg 97-100% ee.
- the racemate is shown in this specification, it is described as DL- before the name of the compound.
- 3-hydroxyaspartic acid may be provided as L-form and D-form, or a mixture of L-form and D-form, for example, racemic form.
- the L-form for a certain optically active compound means that the L-form is present at, for example, an optical purity of 90 to 100% ee, for example, 95 to 100% ee, for example, 97 to 100% ee.
- L-3-hydroxyaspartic acid can be of optical purity 90-100% ee, eg 95-100% ee, eg 97-100% ee.
- the racemate is shown in this specification, it is described as DL- before the name of the compound.
- the stabilizer added to improve the stability of the composition containing LDH of the present disclosure has a final concentration of the compound (active ingredient) of 0.1 mM to 1000 mM in the composition containing LDH, for example, 0. 1 mM-900 mM, 0.1 mM-800 mM, 0.1 mM-700 mM, 0.1 mM-600 mM, 0.1 mM-500 mM, 0.1 mM-400 mM, 0.1 mM-300 mM, 0.1 mM-200 mM, 0.1 mM- 100 mM, 0.1 mM to 90 mM, 0.1 mM to 80 mM, 0.1 mM to 70 mM, 0.1 mM to 60 mM, 0.1 mM to 50 mM, 0.1 mM to 40 mM, 0.1 mM to 30 mM, 0.2 mM to 20 mM, It can be incorporated into a lactate measuring reagent
- an aqueous solution containing a stabilizer and LDH added to improve the stability of the present disclosure can be applied to the electrodes and dried.
- the stabilizer (which may be contained in the composition) is concentrated at the time of drying, and the concentration becomes higher than the final concentration before drying.
- Such a stabilizer for LDH at a high concentration after drying and an electrode coated with the stabilizer are also included in the present disclosure.
- electrodes containing a composition containing a stabilizer are also provided by the present disclosure.
- a composition containing a stabilizer is applied to the electrodes.
- the stabilizer added to improve the stability of the present disclosure can be added at any time during the LDH manufacturing process.
- the stabilizer may be added in the initial stage of the purification process, may be added in the middle of the extraction / purification process, and may be added in the latter half of the manufacturing process, for example, in the stage of freeze-drying / powdering / specification adjustment. It may be added.
- various other components required in the production of compositions containing LDH such as buffers, surfactants, stabilizers, excipients, etc., as long as the stabilizing effect of LDH is not impaired. Can coexist.
- These other components may be included in the stabilizer, may be included in a lactate measuring reagent other than the stabilizer, or may be separately added to the system when the lactate measuring reagent is used.
- the present disclosure provides a composition for measuring lactate or a reagent for measuring lactate, which comprises a stabilizer and LDH added to improve the stability of the composition containing LDH.
- the lactate measuring reagent can be in solution or dry form.
- the LDH stabilizer in the lactate measurement reagent and LDH can be included as separate reagents.
- the compound added to improve the stability of the composition containing LDH in the lactate measuring reagent and LDH can be contained in the same reagent.
- the lactate measuring reagent does not contain LDH, in which case LDH can be added to the measurement solution at the time of lactate measurement.
- the lactate measuring reagent does not contain a stabilizer for LDH, in which case the stabilizer can be added to the measurement solution at the time of lactate measurement.
- the present disclosure provides a method for measuring lactic acid using a stabilizer added to improve the stability of a composition containing LDH and LDH.
- the method for measuring lactic acid may be a method for measuring the concentration of lactic acid.
- the method for measuring lactic acid may be a method for quantifying the concentration of lactic acid.
- the sample to be measured can contain lactic acid.
- the stabilizer added to improve the stability of the composition containing LDH may be included in the lactate measurement reagent in advance, or may be added to the measurement solution at the time of lactate measurement.
- 0.001% by weight to 50% by weight for example, the compound contained in the stabilizer added to improve the stability of the composition containing LDH at the time of measurement is used.
- 0.001% by weight to 25% by weight 0.001% by weight to 20% by weight, 0.001% by weight to 15% by weight, 0.001% by weight to 10% by weight, 0.001% by weight to 9% by weight, 0.001% by weight to 8% by weight, 0.001% by weight to 7% by weight, 0.001% by weight to 6% by weight, 0.001% by weight to 5% by weight, 0.001% by weight to 4% by weight, 0.001% by weight to 3% by weight, 0.1% by weight to 2.5% by weight, 0.001% by weight to 2% by weight, 0.001% by weight to 1% by weight, 0.001% by weight to 0.
- the compound contained in the stabilizer added to improve the stability of the composition containing LDH at the time of measurement is 0.1 mM to 2,000 mM, for example, 0. 1 mM to 1,500 mM, 0.1 mM to 1,000 mM, 0.1 mM to 750 mM, 0.1 mM to 500 mM, 0.1 mM to 400 mM, 0.1 mM to 300 mM, 0.1 mM to 200 mM, 0.1 mM to 100 mM, 0.1 mM to 90 mM, 0.1 mM to 80 mM, 0.1 mM to 70 mM, 0.1 mM to 60 mM, 0.1 mM to 50 mM, 0.1 mM to 40 mM, 0.1 mM to 30 mM, 0.2 mM to 20 mM, 0. It can be included in the measurement solution at a final concentration of 25 mM to
- the stabilizer in the lactic acid measurement method of the present disclosure, may be contained in the lactic acid measurement solution.
- LDH and the sample may be added to the lactic acid measurement solution to start the measurement.
- the LDH may be immobilized on the electrode, and the lactate measurement solution and the sample may be brought into contact with the electrode to measure lactate.
- the stabilizer added to improve the stability of the composition containing LDH of the present disclosure may be contained in the lactate measuring reagent in advance.
- This measurement reagent may or may not contain LDH. If the measurement reagent contains LDH, a sample can be added to it to start lactate measurement. If the measurement reagent does not contain LDH, the sample and LDH can be added thereto (in any order) to start the lactate measurement.
- LDH may be immobilized on an electrode, and the measurement reagent and sample may be brought into contact with the electrode to measure lactic acid.
- the compounds added to improve the stability of the composition containing LDH of the present disclosure do not precipitate LDH.
- ammonium sulphate with a final concentration of 50-70% is excluded as a compound added to improve the stability of the composition containing LDH.
- ammonium sulfate having a final concentration of 50% to 100% is excluded.
- LDH to which this disclosure can be applied
- the LDH applied to the present disclosure catalyzes the reaction of oxidizing the hydroxyl group of lactic acid to produce pyruvic acid in the presence of an electron acceptor, like the known wild-type or mutant LDH.
- the substrate of LDH is lactic acid, which may be provided as a mixture of L-form and D-form, for example, racemic form, or as L-form.
- the activity of LDH utilizes this principle of action, for example, using the following measurement system using phenazinemethsulfate (PMS) and 2,6-dichloroindophenol (DCIP) as electron acceptors as shown in FIG. Can be measured.
- PMS phenazinemethsulfate
- DCIP 2,6-dichloroindophenol
- reaction 1 PMS (reduced form) is generated with the oxidation of L-lactic acid.
- reaction 2 DCIP is reduced as PMS (reduced form) is oxidized.
- the degree of disappearance of this "DCIP (oxidized type)" can be detected as the amount of change in absorbance at a wavelength of 520 nm, and the enzyme activity can be determined based on this amount of change.
- the activity of LDH can be measured according to the following procedure.
- the absorbance at the start of the reaction and over time is measured, the amount of decrease in the absorbance at 520 nm per minute ( ⁇ A 520 ) with the progress of the enzymatic reaction is determined, and the LDH activity is calculated according to Equation 1 of the following equation.
- the LDH activity defines the amount of enzyme that reduces 1 ⁇ mol of DCIP per minute in the presence of L-lactic acid at a concentration of 10 mM at 37 ° C. as 1 U.
- 1.5 is the solution volume (mL) of the reaction reagent + enzyme reagent
- 6.8 is the mmol molecular absorbance coefficient of DCIP (mM -1 cm -1 ) under the present activity measurement conditions
- 0.05 is the enzyme.
- Solution volume (mL) 1.0 is cell optical path length (cm)
- ⁇ A 520 blank is 0.15% (w / v) bovine serum albumin-containing 10 mM potassium phosphate buffer (pH 6.0).
- Is added instead of the enzyme sample solution to start the reaction the amount of decrease in absorbance at 520 nm per minute, and Df represents the dilution factor.
- the thermal stability of LDH can be evaluated by heating LDH at a predetermined temperature for a predetermined time and comparing the activities before and after heating. Specifically, a 150 mM potassium phosphate buffer (pH 7.5) containing 0.15% (w / v) bovine serum albumin as a final concentration containing LDH was allowed to stand on ice at a predetermined temperature (for example, 45). After heating for 15 minutes at ° C., 50 ° C., 55 ° C., and 60 ° C., respectively), LDH activity is measured. The activity of the LDH solution after heating can be calculated with the LDH activity of the LDH solution left on ice as 100 without heat treatment, and the residual activity rate (activity residual rate) (%) can be measured. ..
- improved stability means not only “improvement of thermal stability in solution state” but also “improvement of thermal stability in dry state” or “improvement of thermal stability in drying process”. It also includes “improvement of storage stability (long-term stability) in a solution state” and “improvement of storage stability (long-term stability) in a dry state”. That is, “improved stability” as used in the present disclosure means that a composition containing LDH is coexistent with a specific stabilizer under certain temperature conditions, after heat treatment for a certain period of time, or after long-term storage. It means that the residual activity rate (%) of LDH that is maintained is increased as compared with the case where the above-mentioned stabilizer is not coexistent.
- the residual activity rate (%) is measured by measuring the LDH activity value (a) of the solution before heat treatment or long-term storage and the LDH activity value (b) after heat treatment or long-term storage, respectively (((). It is obtained by calculating b) / (a) ⁇ 100).
- the residual activity rate (%) after heat treatment or long-term storage in the state of coexistence with a specific stabilizer candidate compound was calculated, and this was designated as A, and the same treatment was performed without coexistence with the stabilizer candidate compound.
- the residual activity rate (%) calculated in accordance with the above was B, it was evaluated that the stability of LDH was improved when A> B, and the compound coexisted at this time improved the stability of LDH. It is evaluated that it contributed to.
- the effect of the stabilizer on improving the stability of LDH is, for example, that the residual activity rate (%) is 10% when it is not coexisted with the stabilizer candidate compound, whereas it is coexisted with the stabilizer candidate compound. If the residual activity rate (%) was 15%, it was said to have improved by 5%.
- the effect of the stabilizer on improving the stability of LDH is preferably 2% or more, 3% or more, 4% or more, 5% or more, more preferably 10% or more, 15% or more, still more preferably 20% or more, and more. It can be preferably 30% or more, more preferably 50% or more, still more preferably 60% or more, 70% or more, and 80% or more.
- the effect of the stabilizer on improving the stability of LDH is that it remains when the residual activity rate (%) is 100 when it does not coexist with the stabilizer candidate compound, and preferably when it coexists with the stabilizer candidate compound.
- the relative value of activity is 110 or more, more preferably 130 or more, 150 or more, 200 or more, 250 or more, 300 or more, 350 or more.
- the origin of LDH applicable to the method of the present disclosure is not particularly limited, and prokaryotic origin, eukaryotic origin, microbial origin, fungal origin, plant origin, or animal origin can be used.
- the LDH to which the present disclosure is applicable is flavin-dependent, and the flavin compound which is a coenzyme can be a flavin mononucleotide (FMN) or a flavin adenine dinucleotide (FAD).
- LDH derived from microorganisms includes Ascomycota, preferably Saccharomyceta, more preferably Saccharomycetales, and more preferably Saccharomycetales derived from Pichia, Pichia.
- Ascomycota preferably Saccharomyceta, more preferably Saccharomycetales, and more preferably Saccharomycetales derived from Pichia, Pichia.
- Saccharomyces preferably Saccharomyceta
- the genus Pichia the genus Candida
- the genus Ogataea the genus
- the genus Brettanomyces the genus Cyberlindnera
- the genus Hansenasi the genus Hansenasi.
- Examples of specific preferable microorganisms classified into the genus Pichia include Pichia quadriavzevi, Pichia membranifaciens, and Pichia capsulata.
- Examples of specific preferable microorganisms classified into the genus Candida include Candida inconspirua and Candida boidinii.
- Examples of specific preferable microorganisms classified into the genus Ogataea include Ogataea polymorpha and Ogataea parapolymorpha DL-1.
- Examples of microorganisms classified into the genus Brettanomyces, which are particularly preferable, include Brettanomyces naardenensis and Brettanomyces bruxellensis.
- LDHs derived from microorganisms include Ascomycota, Sordariomycetes, for example, Sordariales, for example, Chaetomiaceae, Chaetomiaceae, Chaetomium, for example, Ph.
- the genus Thermotheromyces may be mentioned, but the present invention is not limited to this.
- Examples of the family Chaetomium (Chaetomiaceae) include, but are not limited to, the genus Chaetomium (genus Chaetomium).
- Examples of the order Sordariales include, but are not limited to, the genus Madurealla.
- the present disclosure also includes a combination of domains constituting these LDHs.
- microorganism classification is for convenience only, and specific microorganisms may be transferred from one classification to another. Also, one genus may be divided into two, or two genera may be integrated into one genus. Essential in the present disclosure are microorganisms that produce LDH, not necessarily modified academic names or classifications. Therefore, even if the scholarly classification of the above microorganisms is changed later, the above disclosure shall be judged based on the microbial classification at the time of filing of the present application. For example, if the family of the genus Madelara is not always clearly defined at the time of filing the application and the family is taxonomically determined after the filing, no matter which family it belongs to, Madurela is at the time of filing the application. Microorganisms belonging to the genus (Madurealla) shall be included in the genus (Madurealla) described above.
- LDHs applicable to the methods of the present disclosure may have some of the other amino acid residues deleted or substituted in those exemplified above, as long as they have lactate dehydrogenase activity, and others. Amino acid residues may be added.
- a gene encoding LDH obtained from LDH-producing organisms as exemplified above by a known genetic engineering method is used, and if necessary, it is partially modified and introduced into an appropriate host microorganism by various known methods.
- the present disclosure can also be applied to recombinant LDH produced in the above-mentioned.
- flavin-dependent lactate dehydrogenase As an example of LDH to which the present disclosure can be preferably applied, flavin-dependent lactate dehydrogenase, more preferably the amino acid sequence shown in SEQ ID NOs: 1, 4, 7, 10 or 70% or more, 71% or more, 72% or more, 73% thereof.
- the region containing the amino acid sequence has low sequence identity and is of low importance in the reaction of lactic acid dehydrogenase with lactic acid. Therefore, among the full-length amino acid sequences, the amino acid sequence at positions 93 to 506 in SEQ ID NO: 1, the amino acid sequence at positions 97 to 502 in SEQ ID NO: 4, the amino acid sequence at positions 100 to 505 in SEQ ID NO: 7, and 99 in SEQ ID NO: 10.
- a lactic acid dehydrogenase containing an amino acid sequence at position 503 or an amino acid sequence having 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, or 95% or more identity with the amino acid sequence.
- the amino acid sequence of positions 1 to 92 in No. 1 the amino acid sequence of positions 1 to 96 in SEQ ID NO: 4, the amino acid sequence of positions 1 to 99 in SEQ ID NO: 7, or the amino acid sequence of positions 1 to 98 in SEQ ID NO: 10. It suffices if the sequence identity is 45% or more, 50% or more, 60% or 70% or more, respectively, or this region may be deleted.
- SEQ ID NO: 4 may be deleted.
- methionine can be optionally added to the beginning of the sequence.
- Pichia kudriavzevii-derived lactate dehydrogenase it is referred to as Pichia kudriavzevii-derived lactate dehydrogenase. The same applies to LDH derived from other microorganisms.
- LDH generally has a signal sequence, a cytochrome domain and a catalytic domain. Since the signal sequence is usually cleaved and is not related to enzyme activity, it is not considered when comparing sequence identities unless otherwise specified. Cytochrome domains often have low sequence identity and are less important for lactate dehydrogenase to react with lactate. Therefore, when comparing sequence identities, cytochrome domains are not considered unless otherwise noted. However, this does not preclude LDH from containing cytochrome domains. In certain embodiments, LDH of the present disclosure has a cytochrome domain. In another embodiment, LDH of the present disclosure does not have a cytochrome domain or has only a partial sequence of cytochrome domains.
- the present inventors have confirmed that the enzyme activity is exhibited even if the cytochrome domain is exchanged for LDHs of different origins. Therefore, with respect to LDH derived from the above-mentioned microorganisms, the catalytic domain from LDH derived from the first microorganism and the cytochrome domain from LDH derived from the second microorganism can also be linked.
- the present disclosure includes such combinations and fusion proteins with respect to LDH derived from the above microorganisms.
- the identity or similarity of the amino acid sequences can be found in GENETYX Ver. It can be calculated by a program such as maximum matching or search homology of 11 (manufactured by Genetics) or a program such as maximum matching or multiple alignment of DNASIS Pro (manufactured by Hitachi Solutions).
- a program such as maximum matching or search homology of 11 (manufactured by Genetics) or a program such as maximum matching or multiple alignment of DNASIS Pro (manufactured by Hitachi Solutions).
- the amino acid sequence identity when two or more LDHs are aligned, the positions of amino acids that are the same in the two or more LDHs can be examined. Based on this information, the same region in the amino acid sequence can be determined.
- lactate dehydrogenase represented by SEQ ID NO: 4 138 to 140, 186 to 194, 217 to 222, 243 to 245, 271 to 278, 280 to 283, 355 to 367, 398.
- the 401st position, the 403rd to the 406th position, the 425th to the 433rd position may correspond to the homology region.
- the amino acid sequence in the homologous region of lactate dehydrogenase of the present disclosure is 75% or more, for example, 76% or more, 77% or more, 78% or more, 79% or more, 80% with the amino acid sequence of the homologous region in SEQ ID NO: 4.
- a known protein engineering method can be used based on the DNA information encoding each of them.
- a method known as Site-Specific Mutagenesis can be generally used.
- the Kramer method Nucleic Acids Res., 12, 9441 (1984): Materials Enzymol., 154,350 (1987): Gene, 37, 73 (1985)
- the Eckstein method Nucleic Acids Res., 13, 8749). 1985: Nucleic Acids Res., 13, 8765 (1985): Nucleic Acids Res, 14, 9679 (1986)
- Kunkel method Proc. Natl. Acid. Sci. USA, 82, 488 (1985).
- the amino acid sequence of LDH may be modified artificially or randomly.
- a conservative amino acid substitution may be introduced at a specific site.
- Conservative amino acid substitution refers to the replacement of one amino acid residue with another amino acid residue having a similar side chain.
- lysine, arginine, and histidine all have basic side chains.
- aspartic acid and glutamic acid have acidic side chains.
- glycine, asparagine, glutamine, serine, threonine, tyrosine, and cysteine all have uncharged polar side chains.
- alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan all have non-polar side chains.
- threonine, valine, and isoleucine all have ⁇ -branched side chains.
- tyrosine, phenylalanine, tryptophan, and histidine all have aromatic side chains. All of these can be subject to mutually conservative amino acid substitutions.
- LDH's active center residues, residues involved in substrate recognition, residues that interact with coenzymes, etc. are important for the functioning of LDH.
- Amino acid residues may or may not be substituted.
- Amino acid residues and sequence motifs important for the function of LDH are known, and when SEQ ID NO: 1 is used as a reference, for example, tyrosine at position 139, tyrosine at position 249, histidine at position 368, and arginine at position 371. Includes alanine at position 193 and leucine at position 225 (see, eg, Biochem., 39, 3266-3275, 2000). These positions and motif sequences do not have to be replaced.
- amino acid substitutions can be performed multiple times in batch units. For example, 1-5 or 1-10 artificial amino acid substitutions may be introduced into LDH as the first round. Then, optionally, 1-5 or 1-10 random amino acid substitutions can be introduced into LDH. This can be repeated multiple times.
- LDH having different sequences at 60 or more, 70 or more, 80 or more, 90 or more, 100 or more, 110 or more, 120 or more, 130 or more, 140 or more, for example, 150 or more.
- the mutant can be easily prepared by repeating the conventional method.
- artificial amino acid substitutions and random amino acid substitutions may be introduced into a specific region of LDH as the first set, which may be repeated once or multiple times. Then, after confirming that the LDH mutant has activity, amino acid substitutions may be introduced once or multiple times into another region of LDH as a second set.
- LDH can also be subjected to high-throughput screening to obtain functional variants.
- a library of transformed or transduced strains carrying the mutated LDH gene may be prepared and used for high-throughput screening based on microtiter plates, or for ultra-high-throughput screening based on droplet microfluidics. May be served. Examples include constructing a combinatorial library of mutant genes encoding variants, followed by phage display (eg Chem. Rev. 105 (11): 4056-72, 2005), yeast display (eg Comb Chem High Throughput Screen. 2008;).
- the library can be used to transform suitable cells, such as electrical competent EBY-100 cells, to obtain approximately 10-7 variants (10 7 ). By repeating this 10 times, a mutant of about 10 8th power can be obtained (10 8 ). Yeast cells transformed in the library can then be subjected to cell sorting. Polydimethoxylsiloxane (PDMS) microfluidic devices made using standard soft lithography methods may be used. A flow focus device can be used to form monodisperse droplets. The formed droplets containing the individual variants can be delivered to a suitable sorting device. The presence or absence of dehydrogenase activity can be used when selecting cells. Mutation introduction and selection may be repeated multiple times.
- suitable cells such as electrical competent EBY-100 cells
- LDH to which this disclosure is applicable is available based on publicly known literature. For example, by culturing the above-mentioned LDH-producing-derived microorganism, or by directly or after mutating the gene encoding natural LDH, it is inserted into an appropriate expression vector and an appropriate host (for example, Escherichia coli). , Yeast, Aspergillus) is cultured, the cells are recovered from the culture solution by centrifugation or the like, and then LDH is collected from the culture.
- an appropriate host for example, Escherichia coli
- the medium for culturing the host cells for example, one or more nitrogen sources such as yeast extract, trypton, peptone, meat extract, corn steep liquor, or soybean or wheat bran leachate, sodium chloride, and monopotassium phosphate.
- nitrogen sources such as yeast extract, trypton, peptone, meat extract, corn steep liquor, or soybean or wheat bran leachate, sodium chloride, and monopotassium phosphate.
- inorganic salts such as dipotassium phosphate, magnesium sulfate, magnesium chloride, ferric chloride, ferrous sulfate or manganese sulfate were added, and if necessary, sugar raw materials, vitamins and the like were added as appropriate. Things are used.
- the initial pH of the medium is not limited, but can be adjusted to, for example, pH 6-9.
- the culture is carried out at a culture temperature of 10 to 42 ° C., preferably a culture temperature of about 25 ° C. for 4 to 24 hours, more preferably a culture temperature of about 25 ° C. for 4 to 8 hours, aeration-stirred deep culture, shaking culture, and standing. It may be carried out by culturing or the like.
- LDH is collected from the culture.
- a usual known enzyme collecting means may be used.
- the cells are subjected to ultrasonic destruction treatment, grinding treatment, etc. by a conventional method, or the enzyme is extracted using a lytic enzyme such as lysozyme, or the bacillus is shaken or left to stand in the presence of toluene or the like. This enzyme can be excreted from the cells. Then, this solution is filtered, centrifuged, etc.
- nucleic acid is removed with streptomycin sulfate, protamine sulfate, manganese sulfate, etc., and then ammonium sulfate, alcohol, acetone, etc. are added thereto. Fractionate, and the precipitate is collected to obtain the crude enzyme of LDH.
- the crude enzyme of LDH can be further purified by any known means.
- a purified enzyme preparation for example, a gel filtration method using Sephadex, Ultrogel, biogel, etc.; an adsorption elution method using an ion exchanger; an electrophoresis method using a polyacrylamide gel, etc.; an adsorption method using hydroxyapatite. Elution method; Precipitation method such as vine sugar density gradient centrifugation method; Affinity chromatography method; Fractionation method using molecular sieve membrane or hollow yarn membrane, etc. was appropriately selected, or purified by carrying out a combination thereof.
- the LDH enzyme preparation of the present disclosure can be obtained.
- the expressed LDH can be secreted directly into the culture medium.
- the concentration of LDH in the present disclosure is not particularly limited, but in solution, it is preferably 0.01 to 1,000 U / mL, more preferably 0.1 to 100 U / mL, and even more preferably 0. It is 1 to 10 U / mL.
- a similar concentration is desirable even in powder or lyophilized products, but for the purpose of preparing powdered specimens, the concentration can be 100 U / mL or more.
- the composition containing LDH of the present disclosure can be provided in a liquid state, but can be pulverized by freeze-drying, vacuum-drying, spray-drying or the like.
- the composition of the buffer solution used for the extraction / purification / powdering of LDH and the stability test is not particularly limited, but is preferably one having a buffering capacity in the pH range of 4 to 9, for example, boric acid, tris hydrochloride, and the like.
- Known commercially available buffers such as potassium phosphate and commercially available good products such as BES, Bicine, Bis-Tris, CHES, EPPS, HEPES, HEPPSO, MES, MOPS, MOPSO, PIPES, POPSO, TAPS, TAPSO, TES and Tricine.
- buffers As the buffering agent as described above, any one type may be used, or two or more types may be used.
- concentration of the buffering agent is not particularly limited as long as it has the required buffering capacity, but a preferable upper limit is 100 mM or less, more preferably 50 mM or less.
- the preferred lower limit is 5 mM or more.
- the content of the buffer in the powder or freeze-dried product is not particularly limited, but is preferably 0.1% (weight ratio) or more, and particularly preferably 0.1 to 30% (weight ratio). Used in range.
- the present disclosure provides a method of screening a stabilizer that improves the stability of LDH.
- This method i) The process of preparing LDH, ii) A step of heat-treating LDH at 35 to 70 ° C. for 5 to 60 minutes. iii) After the above ii), the step of determining the residual activity of LDH, iv) In ii), the step of determining the residual activity of LDH after heat-treating LDH instead of LDH alone in the presence of a candidate substance, and v) It may include a step of comparing the residual activity in iii) with the residual activity in the presence of the candidate substance in iv). When the residual activity in the presence of the candidate substance in iv) is increased more than the residual activity in iii), the candidate substance can be a stabilizer that improves the stability of LDH.
- composition containing LDH By coexisting various stabilizers that improve the stability of LDH as described above with LDH, a composition with improved stability of LDH can be produced.
- the composition containing the enzyme of the present disclosure is not limited to the freeze-dried product, and may be in a solution state in which the dried product is redissolved.
- LDH and various stabilizers may coexist by any method. For example, when both are in a solution state, a composition can be produced by mixing them, and when both are in a powder state, they are mixed in a powder state to produce a composition. be able to. It is also possible to powder LDH and add a stabilizer in the subsequent granulation step. Further, a plurality of kinds of stabilizers can be coexisted in a part in the LDH manufacturing process and the rest in the preparation step of the lactate measuring reagent or the immobilization step on the lactate sensor.
- the present disclosure provides a method of making a composition containing LDH.
- This method i) The process of preparing LDH, ii) A step of heat-treating LDH at 35 to 70 ° C. for 5 to 60 minutes. iii) After the above ii), the step of determining the residual activity of LDH, iv) In ii), the step of determining the residual activity of LDH after heat-treating LDH in the presence of a candidate substance instead of LDH alone. v) The step of comparing the residual activity in iii) with the residual activity in the presence of the candidate substance in iv). vi) When the residual activity in the presence of the candidate substance in iv) is higher than the residual activity in iii) above, the composition is improved in the stability of LDH by coexisting the candidate substance with LDH.
- the process of manufacturing things May include.
- the present disclosure provides a method for suppressing a decrease in activity or inactivation of lactate dehydrogenase in a method for producing an electrode, which comprises a step of applying lactate dehydrogenase to the electrode.
- This method i) Steps to prepare a solution containing lactate dehydrogenase, ii) An anion, monosaccharide, disaccharide, polyethylene glycol selected from the group consisting of monocarboxylic acid, dicarboxylic acid, tricarboxylic acid, tetracarboxylic acid, polycarboxylic acid, phosphoric acid, sulfuric acid or salts thereof in the solution.
- a step of applying a solution containing the lactate dehydrogenase and the stabilizer to the electrode, iv) The step of drying the applied solution, May include.
- the electrode coated with lactate dehydrogenase may be included in the lactate sensor.
- the mediator when the LDH is used immobilized on an electrode or when the LDH is used without immobilization, the mediator is known as a mediator such as 1-methoxy-5-methylphenazinenium methylsulfate (mPMS).
- mPMS 1-methoxy-5-methylphenazinenium methylsulfate
- Luthenium complexes such as hexaammine ruthenium, osmium complexes such as osmium-2,2'-bipyridine, and phenylenediamine compounds such as p-phenylenediamine and N-isopropyl-N'-phenyl-p-phenylenediamine can be used. ..
- these mediators can also be used after being modified with a polymer such as polyvinyl imidazole, polyethyleneimine, or polyacrylic acid. Further, these mediators can also be immobilized on GDH using a cross-linking reagent or the like. All of these are incorporated herein by reference. Further, these mediators can also be immobilized on the electrode after the surface of the electrode is activated by acid treatment or the like. Materials such as carbon, gold, and platinum can be used for the electrodes.
- the final concentration of the mediator added to the sample solution is not particularly limited, and is, for example, 1 pM to 1 M, 1 pM to 100 mM, 1 pM to 20 mM, 1 pM to 10 mM, 1 pM to 5 mM, 2 pM to 1 mM, 3 pM to 800 ⁇ M, 4 pM to 600 ⁇ M, 5 pM. It can be in the range of ⁇ 500 ⁇ M, 6 pM to 400 ⁇ M, 7 pM to 300 ⁇ M, 8 pM to 200 ⁇ M, 9 pM to 100 ⁇ M, 10 pM to 50 ⁇ M.
- the order of addition of the mediator and other reagents is not limited, and simultaneous or sequential addition may be used.
- composition containing LDH of the present disclosure a reagent for measuring lactic acid, a lactic acid assay kit, and a lactic acid sensor having improved stability of LDH can be produced, and lactic acid can be measured using the reagent. ..
- the reagents for measuring lactate of the present disclosure typically include reagents necessary for measurement such as LDH, buffer solution, mediator, lactate standard solution for preparing a calibration curve, and instructions for use to improve the stability of LDH. Contains stabilizers that contribute to the improvement.
- the reagent for measuring lactate of the present disclosure can be provided, for example, as a lyophilized reagent or as a solution in a suitable storage solution.
- the lactic acid measuring reagent of the present disclosure can measure lactic acid in the same manner as the conventional lactic acid measuring reagent, and the stability of LDH is improved when the lactic acid measuring reagent of the present disclosure is used. Therefore, the reagent for measuring lactate of the present disclosure exhibits better thermal stability and storage stability.
- the lactate assay kits of the present disclosure typically include a sufficient amount of LDH for at least one lactate measurement and the buffer, mediator, and lactate standard solution for making the calibration curve required for the assay. Contains a stabilizer that contributes to improving the stability of LDH.
- the lactate assay kit of the present disclosure can measure lactate in the same manner as the conventional lactate assay kit, and the stability of LDH is improved when the lactate assay kit of the present disclosure is used.
- the kits for lactate assays of the present disclosure exhibit better thermal and storage stability.
- the present disclosure also provides a lactate sensor with improved thermal stability of LDH.
- the sensor has electrodes.
- the sensor has a working electrode and a counter electrode as electrodes.
- the sensor has a working electrode, a counter electrode and a reference electrode as electrodes.
- LDH is immobilized on an electrode.
- a carbon electrode, a gold electrode, a platinum electrode, or the like can be used, and the enzyme of the present disclosure can be immobilized on the electrode.
- Immobilization methods include a method using a cross-linking reagent, a method of encapsulating in a polymer matrix, a method of coating with a dialysis membrane, a method of using a photocrosslinkable polymer, a conductive polymer, an oxidation-reduced polymer, or the like, or together with a mediator. It may be fixed in a polymer or adsorbed and fixed on an electrode, or these may be used in combination. Typically, LDH of the present disclosure is immobilized on a carbon electrode with glutaraldehyde and then treated with a reagent having an amine group to block glutaraldehyde.
- the composition or reagent containing the stabilizer of the present disclosure can be used for various electrochemical measurements using a potentiostat, a galvanostat, or the like, together with an electrode on which LDH is immobilized, an enzyme sensor, or the like.
- Electrochemical measurement methods include various methods such as amperometry such as chronoamperometry, potential step chronoamperometry, voltammetry such as cyclic voltammetry, differential pulse voltammetry, potentialometry and coulometry.
- amperometry such as chronoamperometry, potential step chronoamperometry, voltammetry such as cyclic voltammetry, differential pulse voltammetry, potentialometry and coulometry.
- the lactic acid concentration in a sample can be calculated by measuring the current when lactic acid is reduced by the amperometry method.
- the applied voltage may be, for example, -1,000 mV to +1,000 mV (vs. Ag / AgCl), although it depends on the conditions and the setting of the
- Electrodes can be formed on an insulating substrate. Specifically, electrodes can be formed on a substrate by a photolithography technique or a printing technique such as screen printing, gravure printing, or flexographic printing. Examples of the material of the insulating substrate include silicon, glass, ceramic, polyvinyl chloride, polyethylene, polypropylene, polyester and the like, and those having strong resistance to various solvents and chemicals can be used. Further, carbon cloth, carbon paper, or buckypaper can be used as the base of the electrode. The area of the working electrode can be set according to the desired response current.
- the area of the working electrode is 1 mm 2 or more, 1.5 mm 2 or more, 2 mm 2 or more, 2.5 mm 2 or more, 3 mm 2 or more, 4 mm 2 or more, 5 mm 2 or more, 6 mm 2 or more, 7 mm 2 or more, 8 mm. 2 or more, 9 mm 2 or more, 10 mm 2 or more, 12 mm 2 or more, 15 mm 2 or more, 20 mm 2 or more, 30 mm 2 or more, 40 mm 2 or more, 50 mm 2 or more, 1 cm 2 or more, 2 cm 2 or more, 3 cm 2 or more, 4 cm 2 or more , 5 cm 2 or more, for example 10 cm 2 or more.
- the area of the working electrode can be 10 cm 2 or less, 5 cm 2 or less, for example 1 cm 2 or less.
- the opposite pole can be similar.
- carbon nanotubes, graphene, Ketjen black, etc. can be immobilized on the working surface to increase the apparent surface area.
- the apparent area can be increased by 10 times or more, 50 times or more, 100 times or more, and 1000 times or more.
- the lactic acid concentration can be measured by chronoamperometry, for example, as follows. Put buffer in a constant temperature cell and add mediator to keep it at a constant temperature. As the working electrode, the LDH-immobilized electrode of the present disclosure is used, and a counter electrode (for example, a platinum electrode) and a reference electrode (for example, Ag / AgCl electrode) are used. A constant voltage is applied to the carbon electrode, and after the current becomes steady, a sample containing lactic acid is added and the increase in current is measured. The lactic acid concentration in the sample can be calculated according to the calibration curve prepared with the standard concentration lactic acid solution.
- a counter electrode for example, a platinum electrode
- a reference electrode for example, Ag / AgCl electrode
- the lactic acid sensor of the present disclosure can measure lactic acid by using the same as the conventional lactic acid sensor, and when the lactic acid sensor of the present disclosure is used, the stability of LDH is improved.
- the kit for the lactate sensor shows better thermal stability and storage stability. Further, also in the step of immobilizing LDH on the sensor, the degree of deactivation due to heat at the time of immobilization can be reduced, so that the amount of LDH used for immobilization can be reduced.
- the present disclosure provides an anode electrode comprising an LDH composition with improved thermal stability.
- LDH may be immobilized on an electrode of the battery.
- the anode electrodes of the present disclosure can provide a battery in combination with a cathode electrode and a resistor.
- the present disclosure provides a power generation method using the above-mentioned battery.
- a battery comprising the LDH composition with improved thermal stability of the present disclosure is provided.
- the present disclosure provides an anode or cathode for a fuel cell and a fuel cell comprising the anode or cathode.
- This fuel cell contains the LDH composition with improved thermal stability of the present disclosure.
- the present disclosure relates to a power generation method using a battery containing the LDH composition having improved thermal stability, as well as an LDH immobilized on an anode electrode and fueled with a substrate corresponding to the LDH, for example, lactic acid. And provide a method of generating electricity.
- the fuel cell of the present disclosure comprises an anode, a fuel tank, a cathode, and an electrolyte containing the LDH composition with improved thermal stability described above.
- An artificial electron mediator may be adsorbed on the anode or cathode.
- the artificial electronic mediator include, but are not limited to, the known mediators described above and the phenylenediamine compounds described in Japanese Patent No. 6484741 and Japanese Patent No. 6484742.
- the fuel cell of the present disclosure can arrange a load resistance between the anode and the cathode, if necessary, and can be provided with wiring for that purpose. In certain embodiments, the load resistance is part of the fuel cell of the present disclosure.
- the load resistance is not part of the fuel cell of the present disclosure, and the fuel cell of the present disclosure is configured to be connectable to a suitable load resistance.
- oxidoreductase forms part of the anode.
- the redox enzyme may be in close proximity to or in contact with the anode, may be immobilized, or may be adsorbed.
- the fuel tank contains a compound that serves as a substrate for oxidoreductase immobilized on an electrode.
- the fuel cell of the present disclosure may have an ion exchange membrane that separates the anode and cathode. The ion exchange membrane can have pores of 1 nm to 20 nm.
- the anode can be a common electrode such as a carbon electrode.
- a common electrode such as a carbon electrode.
- an electrode made of a conductive carbon substance such as carbon black, graphite, or activated carbon, or an electrode made of a metal such as gold or platinum can be used. Specific examples thereof include carbon paper, carbon cloth, glassy carbon, and HOPG (highly oriented pyrolytic graphite).
- an electrode catalyst generally used in a fuel cell such as platinum or platinum alloy is used as a carbonaceous material such as carbon black, graphite or activated carbon, or a conductive material made of gold, platinum or the like.
- an electrode carried on the body or a conductor made of an electrode catalyst itself such as platinum or a platinum alloy as a cathode electrode, and supply an oxidizing agent (catalyst side substrate, oxygen, etc.) to the electrode catalyst. can.
- a substrate-reducing enzyme electrode can be used as a cathode paired with an anode composed of the substrate-oxidizing enzyme electrode as described above.
- the redox enzyme that reduces the oxidizing agent include known enzymes such as laccase and bilirubin oxidase.
- a known electron transfer mediator may be used, if necessary.
- the oxidizing agent include oxygen and the like.
- an oxygen-selective membrane eg, a dimethylpolysiloxane membrane
- impurities such as ascorbic acid and uric acid
- the power generation method of the present disclosure includes a step of supplying a compound serving as a substrate for oxidoreductase as a fuel to an anode having oxidoreductase.
- a compound serving as a substrate for oxidoreductase as a fuel to an anode having oxidoreductase.
- the substrate is oxidized and the electrons generated at the same time are generated by the oxidoreductase, which is an electron transfer mediator that mediates the electron transfer between the oxidoreductase and the electrode, for example, phenylene. It is transferred to a diamine-based compound, and electrons are transferred to a conductive substrate (anode electrode) by the electron transfer mediator.
- An electric current is generated when electrons reach the cathode electrode from the anode electrode through wiring (external circuit).
- the protons (H + ) generated in the above process move in the electrolyte solution to the cathode electrode. Then, at the cathode electrode, the protons that have moved from the anode in the electrolyte solution, the electrons that have moved from the anode side through the external circuit, and the oxidizing agent (cathode side substrate) such as oxygen and hydrogen peroxide react with each other. Water is produced. This can be used to generate electricity.
- a DNA construct was prepared by inserting the ScLDH gene, which is the target gene, into the multi-cloning site of the plasmid pKK223-3 by a conventional method. Specifically, at the In-Fusion Cloning Site at the multi-cloning site of pKK223-3, the ScLDH gene is ligated according to the plasmid attached to the kit using the In-Fusion HD Cloning Kit (manufactured by Clontech). Then, a plasmid for expression (pKK223-3-ScLDH) was obtained.
- Escherichia coli JM109 was transformed with these plasmids, and Escherichia coli JM109 (pKK223-3-ScLDH) strain was cultivated in 3 mL of LB-amp medium [1% (w / v) bactotripton, 0.5% (w). / V) Peptone, 0.5% (w / v) NaCl, 50 ⁇ g / mL ampicillin] was inoculated and cultured at 37 ° C. for 16 hours with shaking to obtain a culture. The culture was collected by centrifugation at 10,000 ⁇ g for 1 minute to obtain bacterial cells. From this cell, a recombinant plasmid pKK223-3-ScLDH was obtained using GenElute Plasmamid Miniprep Kit (manufactured by Sigma-Aldrich).
- SEQ ID NO: 3 which is the amino acid sequence of Pichia kudriavzevii-derived lactic acid dehydrogenase (PkLDH)
- PkLDH Pichia kudriavzevii-derived lactic acid dehydrogenase
- SEQ ID NO: 6 which is the amino acid sequence of Candida inconspica-derived lactic acid dehydrogenase (CaLDH)
- SEQ ID NO: 7 the 505 amino acid represented by SEQ ID NO: 7 from which the 2-67 position has been removed is encoded by SEQ ID NO: 8.
- the 1518 bp gene (including the stop codon TAA) shown in (1) was obtained as double-stranded DNA by PCR of a gene fragment, which is a routine method.
- SEQ ID NO: 9 which is the amino acid sequence of Ogataea parapolymorpha-derived lactic acid dehydrogenase (OgLDH)
- SEQ ID NO: 10 the 503 amino acids represented by SEQ ID NO: 10 with the 2-56 position removed are encoded by SEQ ID NO: 11.
- the 1512 bp gene (including the stop codon TAA) shown in (1) was obtained as double-stranded DNA by PCR of a gene fragment, which is a routine method.
- the target gene was inserted into the multi-cloning site of the plasmid pKK223-3 by a conventional method in the same manner as when preparing the plasmid for ScLDH expression, and the recombinant plasmids pKK223-3-PkLDH and pKK223-3-3 were inserted. CalDH and pKK223-3-OgLDH were obtained, respectively.
- Escherichia coli BL21 strain was used as an LDH-producing bacterium.
- Escherichia coli BL21 (pKK223-3-ScLDH) strain cultivated with pKK223-3-ScLDH was prepared by poking colonies of the strain previously cultured on an LB plate medium (containing 100 ⁇ g / mL ampicillin) with a pinch, and 2 mL (100 ⁇ g) of the LB medium. In a small test tube containing / mL ampicillin), the cells were shake-cultured at 25 ° C. and 160 rpm for 24 hours.
- This culture medium is transferred to a 0.5 L Sakaguchi flask containing 250 mL of LB medium (50 ⁇ g / mL ampicillin, 1 mM isopropyl- ⁇ -thiogalactopyranoside (hereinafter referred to as IPTG)), and transferred to a 0.5 L volume Sakaguchi flask at 25 ° C. and 130 rpm for 30 hours. It was shake-cultured. Similarly, the Escherichia coli BL21 (pKK223-3-PkLDH) strain transduced with pKK223-3-PkLDH is shaken overnight at 30 ° C.
- IPTG isopropyl- ⁇ -thiogalactopyranoside
- Escherichia coli BL21 (pKK223-3-CaLDH) strain and Escherichia coli BL21 (pKK223-3-OgLDH) strain transduced with pKK223-3-CaLDH or pKK223-3-OgLDH were added to 2 mL (100 ⁇ g / mL ampicillin) of LB medium. ) was placed in a small test tube and cultured at 30 ° C. and 160 rpm with shaking overnight. The entire volume of this culture solution was transferred to a 0.5 L Sakaguchi flask containing 250 mL of LB medium (50 ⁇ g / mL ampicillin, 1 mM IPTG), and cultured at 30 ° C. and 130 rpm for 30 hours with shaking.
- the culture solution was centrifuged at 6,000 rpm at 25 ° C. for 5 minutes to remove the supernatant, and the cells were collected. Then, the obtained cells were suspended in 20 mM potassium phosphate buffer (pH 7.5). The above cell suspension was ultrasonically crushed using an ultrasonic homogenizer US-150E (manufactured by Nissei Tokyo Office) until the suspension became translucent, and the distance was 10 minutes at 9,000 rpm and 4 ° C. The supernatant was collected with care. Anion exchange chromatography purification was performed on the supernatant of the cell disruption solution containing various LDHs excluding ScLDH.
- a supernatant containing various LDHs was added to the resin to 10 mL of Q Sepharose Fast Flow (manufactured by Cytiva) equilibrated with 20 mM potassium phosphate buffer (pH 7.5). .. Next, 20 mM potassium phosphate buffer (pH 7.5) containing 0 to 500 mM NaCl was added, and a fraction having high LDH activity was recovered. The resulting fraction showing LDH activity was concentrated using Amicon® Ultra-15 Centrifugal Filters Ultracel®-30K.
- each of the recovered fractions was equilibrated with a 10 mM potassium phosphate buffer (pH 7.0 for PkLDH, pH 7.5 for CalDH and OgLDH) containing 150 mM sodium chloride, and the HiRoad 26/600 Superdex 200 pg column (Cytiva) was used.
- the obtained fraction was analyzed by SDS-PAGE, and the fraction showing a single band and showing LDH activity was recovered and used as a purified sample of various LDH.
- the residual activity rate (%) with and without the addition of the LDH stabilizer is compared according to the above-mentioned method for evaluating the thermal stability of LDH. I searched for.
- the thermal stability of LDH was evaluated by heating LDH at a predetermined temperature for a predetermined time and comparing the activities before and after heating. Specifically, a 150 mM potassium phosphate buffer (pH 7.5) containing 0.15% (w / v) bovine serum albumin as a final concentration containing LDH was allowed to stand on ice at a predetermined temperature (for example, 45).
- LDH activity was measured.
- the LDH activity of the LDH solution that had been left to stand on ice without heat treatment was measured, the activity of the LDH solution after heating was calculated with the activity as 100, and the residual activity rate (%) was measured. .. Specifically, the residual activity rate (%) is measured by measuring the LDH activity value (a) of the solution before heat treatment or long-term storage and the LDH activity value (b) after heat treatment or long-term storage, respectively (((). b) / (a) ⁇ 100) was calculated.
- LDH activity was measured according to the following procedure. 1M potassium phosphate buffer (pH 7.5) 170 ⁇ L, 50 mM DL-lactic acid (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd., product number 128-00056) 300 ⁇ L and 1.8 mM DCIP solution 250 ⁇ L, ultrapure water 680 ⁇ L were mixed. It was kept warm at 37 ° C. for 2 minutes or more.
- 1.5 is the solution volume (mL) of the reaction reagent + enzyme reagent
- 6.8 is the mmol molecular absorbance coefficient of DCIP (mM -1 cm -1 ) under the present activity measurement conditions
- 0.05 is the enzyme.
- Solution volume (mL) 1.0 is cell optical path length (cm)
- ⁇ A 520 blank is 0.15% (w / v) bovine serum albumin-containing 10 mM potassium phosphate buffer (pH 6.0).
- Is added instead of the enzyme sample solution to start the reaction the amount of decrease in absorbance at 520 nm per minute, and Df represents the dilution factor.
- an LDH solution (2 U / mL) containing 150 mM potassium phosphate buffer, 300 mM various compounds and 0.15% (w / v) bovine serum albumin (BSA) was used. , The residual activity rate of LDH was calculated. The pH of the PkLDH solution was adjusted to 7.5 after the addition of various compounds. The heat treatment was performed at 55 ° C. for 15 minutes. As a comparative example, the same test was conducted even when an LDH solution prepared without adding various compounds was used. Unless otherwise specified, the reagents purchased from Tokyo Chemical Industry Co., Ltd. were used thereafter.
- L- (+)-tartaric acid was added.
- Table 2 LDH is stable when D-malic acid, DL-3-hydroxyaspartic acid, oxaloacetate, D- (-)-tartaric acid, and L- (+)-tartaric acid are added. It became clear that the sex was improved.
- the active residual rate (%) without compound addition is 30%.
- the activity residual rate (%) exceeded 50%, and high stability was confirmed.
- DL-3-hydroxyaspartic acid, DL-leucine acid, and DL-phenyllactic acid had active residual rates (%) of 77%, 92%, and 87%, respectively. That is, the addition of DL-3-hydroxyaspartic acid, DL-leucine acid, and DL-phenyllactic acid revealed a remarkably high effect of improving the stability of LDH.
- the heat treatment was carried out at 50 ° C. for 15 minutes.
- an LDH solution prepared without adding various compounds containing 150 mM potassium phosphate buffer, 0.15% (w / v) BSA adjusted to pH 7.5
- the test was conducted in the same manner.
- the effect of improving the stability of LDH by maltose monohydrate was 5%
- the effect of improving the stability of LDH by ethylenediaminetetraacetic acid was 56%. That is, it was clarified that the thermal stability of LDH was improved by adding maltose monohydrate or ethylenediaminetetraacetic acid.
- the heat treatment was carried out at 50 ° C. for 15 minutes.
- an LDH solution prepared without adding various compounds containing 150 mM potassium phosphate buffer, 0.15% (w / v) BSA adjusted to pH 7.5
- the test was conducted in the same manner.
- glycine has an effect of improving the stability of LDH by 11%
- L-lysine hydrochloride has an effect of improving the stability of LDH by 66%
- L-histidine has an effect of improving the stability of LDH by 27%
- disodium malonate has an effect of improving the stability of LDH.
- the effect of improving the stability of LDH was 96%.
- the heat treatment was carried out at 40 ° C. for 15 minutes.
- an LDH solution prepared without adding various compounds containing 150 mM potassium phosphate buffer, 0.15% (w / v) BSA adjusted to pH 7.5
- the test was conducted in the same manner.
- the effect of improving the stability of ScLDH by L-malic acid was 41%
- the effect of improving the stability of ScLDH by disodium malonate was 26%
- the effect of improving the stability of LDH by ammonium sulfate was 24%. That is, it was clarified that the thermal stability of ScLDH was improved by adding L-malic acid, disodium malonic acid, and ammonium sulfate as well as PkLDH, CaldH, and OgLDH.
- the active residual rate (%) without compound addition is 27%, whereas the active residual rate (%) exceeds 70%, and the stability is remarkably high.
- stabilizers found so far such as L-malic acid and disodium malonic acid, exert a stabilizing effect not only in the phosphate buffer solution but also when added to the HEPES buffer solution, and the buffer solution has a stabilizing effect. It was found to be effective as a stabilizer regardless of the type. This suggests that the various compounds found above that contribute to the improvement of stabilization can exert an effect regardless of the type of buffer solution.
- the degree of the effect of improving the stability of LDH by adding various stabilizers is the condition that the residual activity rate (%) of LDH after addition of various stabilizers is measured and the stabilizer is not added. It was evaluated by comparing with the residual activity rate (%) in. Specifically, the relative value of the residual activity rate under the condition of adding the stabilizer when the residual activity rate when the stabilizer for comparison is not added is 100 is calculated, and this is more than 100. Larger ones were evaluated as having the effect of improving stability. For example, when the residual activity rate under the condition without the stabilizer to be compared is 30% and the residual activity rate under the condition with the stabilizer added is 45%, the relative value of the residual activity is 150. Will be.
- the stability of LDH was improved when sodium hyaluronate, methyl glycol chitosan, sodium carboxymethyl cellulose, and poly (diallyldimethylammonium chloride) were added (Table 7).
- the polymer that can function as a stabilizer may have any structure as long as the functional group of the side chain has an anionic substance such as a carboxy group or a cationic substance such as an amino group. It is suggested that it exerts a stabilizing effect regardless of the structure.
- the prepared electrode was connected to the ALS electrochemical analyzer 814D (manufactured by BAS) using a dedicated connector (DRP-CAC, manufactured by Drop Sense). Next, 100 ⁇ L of 2 mM mPMS / PBS solution was added dropwise to dissolve the dried LDH. The applied voltage was +200 mV (vs Ag / Ag + ). A solution of L-sodium lactate was added, and the response current value 5 seconds after the start of measurement was recorded. As a result, as shown in Table 8, when any of the compounds was added, the current value was larger than that when the compound was not added.
- LDH exhibits sufficient activity even when it coexists with the compound added when reacting with 0 to 10 mM lactic acid on the electrode. Although not shown in the table, the LDH stability improving effect was confirmed even when 10 mM of lactic acid was present, as in the case of 5 mM of lactic acid.
- SEQ ID NO: 1 Lactate dehydrogenase (ScLDH) derived from Saccharomyces cerevisiae (however, wild-type positions 1 to 85 are removed)
- SEQ ID NO: 2 Nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 1
- SEQ ID NO: 3 Amino acid sequence of lactic acid dehydrogenase (PkLDH) derived from Pichia kudriavzevii
- SEQ ID NO: 4 SEQ ID NO: 3 from which the sequence at positions 2 to 77 of SEQ ID NO: 3 has been removed.
- Nucleotide sequence encoding the amino acid sequence of 4 SEQ ID NO: 6 Amino acid sequence of lactic acid dehydrogenase (CaLDH) derived from Candida inconspica SEQ ID NO: 7 Sequence No. 6 from which positions 2 to 67 have been removed SEQ ID NO: 8 Encodes the amino acid sequence of SEQ ID NO: 7.
- Nucleotide sequence SEQ ID NO: 9 Amino acid sequence of lactic acid dehydrogenase (OgLDH) derived from Ogataea parapolymorpha SEQ ID NO: 10 Sequence No. 9 from which positions 2 to 56 have been removed SEQ ID NO: 11 Nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 10.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
[1] フラビン化合物を補酵素とする乳酸デヒドロゲナーゼを含む組成物に、モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩(硫酸アンモニウムを除く)からなる群より選択されるアニオン、単糖、二糖、ポリエチレングリコール、若しくはイオン性ポリマーを1種類以上共存させる工程を含む、乳酸デヒドロゲナーゼ含有組成物の熱安定性を向上させる方法。
[2] 乳酸デヒドロゲナーゼが、サッカロマイセス属、ピキア属、カンディダ属、オガタエア属、ブレタノマイセス属、シベルリンドネラ属、ハンセニアスポラ属、カザツタニア属、クルイウェロマイセス属、ラチャンセア属、ナウモヴォジマ属、テトラピシスポラ属、トルラスポラ属、ヴァンデルワルトジマ属、ジゴサッカロマイセス属、ジゴトルラスポラ属、ミセリオフトラ属、サーモセロマイセエス属、カエトミウム属、又はマドゥレラ属由来の乳酸デヒドロゲナーゼである、1に記載の方法。
[3] 乳酸デヒドロゲナーゼが以下の(i)及び/または(ii)である、1に記載の乳酸デヒドロゲナーゼ含有組成物の熱安定性を向上させる方法、
(i)配列番号1、配列番号4、配列番号7、又は配列番号10に示されるアミノ酸配列との同一性が70%以上又は80%以上のアミノ酸配列を有する乳酸デヒドロゲナーゼ、
(ii)配列番号4の第138~140位、186~194位、217~222位、243~245位、271~278位、280~283位、355~367位、398~401位、403~406位及び425~433位のアミノ酸配列からなる相同性領域におけるアミノ酸配列と当該乳酸デヒドロゲナーゼの対応する位置の相同性領域におけるアミノ酸配列とが80%以上又は90%以上の配列同一性を有する乳酸デヒドロゲナーゼ。
[4] モノカルボン酸がグルコン酸、ロイシン酸、3-フェニル乳酸、グリシン、リジン、ヒスチジン及びアルギニンからなる群より選択され、
ジカルボン酸がリンゴ酸、コハク酸、マレイン酸、フマル酸、マロン酸、メチルマロン酸、オキサロ酢酸、酒石酸、シュウ酸、スクシン酸、グルタル酸、α-ケトグルタル酸、アジピン酸、ピメリン酸、スベリン酸、アゼライン酸、セバシン酸、フタル酸、イソフタル酸、テレフタル酸、グルタコン酸、タルトロン酸、ムコン酸、メサコン酸、シトラコン酸、メコン酸、3-3’ジメチルグルタル酸、イタコン酸、グルタミン酸、アスパラギン酸、及び3-ヒドロキシアスパラギンからなる群より選択され、
トリカルボン酸がクエン酸、イソクエン酸、アコニット酸、トリメシン酸、1,2,3-プロパントリカルボン酸、及び2-ホスホノブタン-1,2,4-トリカルボン酸からなる群より選択され、
テトラカルボン酸がエチレンジアミン四酢酸から選択され、
リン酸がリン酸塩及びピロリン酸塩からなる群より選択され、
硫酸が硫酸塩から選択され、
単糖がmyo-イノシトールからなる群より選択され、
二糖がスクロース、トレハロース、及びマルトースからなる群より選択され、又は
ポリエチレングリコール、
又は
イオン性ポリマーがアニオン性ポリマーであるか、若しくはカチオン性ポリマーであり、
アニオン性ポリマーがポリアクリル酸、ヒアルロン酸、及びカルボキシメチルセルロース若しくはこれらの塩からなる群より選択されるか、若しくは、
カチオン性ポリマーがポリリジン、ポリエチレンイミン、メチルグリコールキトサン、及びポリ(塩化ジアリルジメチルアンモニウム)から選択される、1~3のいずれかに記載の乳酸デヒドロゲナーゼ含有組成物の熱安定性を向上させる方法。
[5] モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩からなる群より選択されるアニオン、単糖、二糖、アニオン性ポリマー若しくはカチオン性ポリマーが溶液中において、0.01重量%から30重量%の範囲で含む、1~4のいずれかに記載の乳酸デヒドロゲナーゼ含有組成物の熱安定性を向上させる方法。
[6] フラビン化合物を補酵素とする乳酸デヒドロゲナーゼ及び、モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩(硫酸アンモニウムを除く)からなる群より選択されるアニオン、単糖、二糖、ポリエチレングリコール、イオン性ポリマーのいずれか1種類以上の化合物を含む乳酸測定用組成物。
[7] 乳酸デヒドロゲナーゼが、サッカロマイセス属、ピキア属、カンディダ属、オガタエア属、ブレタノマイセス属、シベルリンドネラ属、ハンセニアスポラ属、カザツタニア属、クルイウェロマイセス属、ラチャンセア属、ナウモヴォジマ属、テトラピシスポラ属、トルラスポラ属、ヴァンデルワルトジマ属、ジゴサッカロマイセス属、ジゴトルラスポラ属、ミセリオフトラ属、サーモセロマイセエス属、カエトミウム属、又はマドゥレラ属由来の乳酸デヒドロゲナーゼである、6に記載の乳酸測定用組成物。
[8] 乳酸デヒドロゲナーゼが以下の(i)及び/または(ii)である、6に記載の組成物、
(i)配列番号1、配列番号4、配列番号7、又は配列番号10に示されるアミノ酸配列との同一性が70%以上又は80%以上のアミノ酸配列を有する乳酸デヒドロゲナーゼ、
(ii)配列番号4の第138~140位、186~194位、217~222位、243~245位、271~278位、280~283位、355~367位、398~401位、403~406位及び425~433位のアミノ酸配列からなる相同性領域におけるアミノ酸配列と当該乳酸デヒドロゲナーゼの対応する位置の相同性領域におけるアミノ酸配列とが80%以上又は90%以上の配列同一性を有する乳酸デヒドロゲナーゼ。
[9] モノカルボン酸がグルコン酸、ロイシン酸、3-フェニル乳酸、グリシン、リジン、ヒスチジン及びアルギニンからなる群より選択され、
ジカルボン酸がリンゴ酸、コハク酸、マレイン酸、フマル酸、マロン酸、メチルマロン酸、オキサロ酢酸、酒石酸、シュウ酸、スクシン酸、グルタル酸、α-ケトグルタル酸、アジピン酸、ピメリン酸、スベリン酸、アゼライン酸、セバシン酸、フタル酸、イソフタル酸、テレフタル酸、グルタコン酸、タルトロン酸、ムコン酸、メサコン酸、シトラコン酸、メコン酸、3-3’ジメチルグルタル酸、イタコン酸、グルタミン酸、アスパラギン酸、及び3-ヒドロキシアスパラギンからなる群より選択され、
トリカルボン酸がクエン酸、イソクエン酸、アコニット酸、トリメシン酸、1,2,3-プロパントリカルボン酸、及び2-ホスホノブタン-1,2,4-トリカルボン酸からなる群より選択され、
テトラカルボン酸がエチレンジアミン四酢酸から選択され、
リン酸がリン酸塩及びピロリン酸塩からなる群より選択され、
硫酸が硫酸塩から選択され、
単糖がmyo-イノシトールからなる群より選択され、
二糖がスクロース、トレハロース、及びマルトースからなる群より選択され、又は
ポリエチレングリコール、
又は
イオン性ポリマーがアニオン性ポリマーであるか、若しくはカチオン性ポリマーであり、
アニオン性ポリマーがポリアクリル酸、ヒアルロン酸、及びカルボキシメチルセルロース若しくはこれらの塩からなる群より選択され、
カチオン性ポリマーがポリリジン、ポリエチレンイミン、メチルグリコールキトサン、及びポリ(塩化ジアリルジメチルアンモニウム)から選択される、6~8のいずれかに記載の乳酸測定用組成物。
[10] モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩(硫酸アンモニウムを除く)からなる群より選択されるアニオン、単糖、二糖、ポリエチレングリコール、若しくはアニオン性ポリマー又はカチオン性ポリマーが溶液中において、0.01重量%から30重量%の範囲で含む、6~9のいずれかに記載の乳酸測定用組成物。
[11] 6~10のいずれかに記載の組成物を含む乳酸測定用キット。
[12] フラビン化合物を補酵素とする乳酸デヒドロゲナーゼ及び、モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩からなる群より選択されるアニオン、単糖、二糖、ポリエチレングリコール、イオン性ポリマーのいずれか1種類以上の化合物を含む組成物を含む電極。
[13] 12に記載の電極を含む乳酸センサー。
[14] 12に記載の電極を含む燃料電池。
[15] 乳酸デヒドロゲナーゼを電極に塗布する工程を含む電極の製造方法において、乳酸デヒドロゲナーゼの活性低下又は失活を抑制する方法であって、
i) 乳酸デヒドロゲナーゼを含む溶液を用意する工程、
ii)前記溶液に、モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩からなる群より選択されるアニオン、単糖、二糖、ポリエチレングリコール、イオン性ポリマーからなる群より選択される1以上の安定化剤を添加する工程、
iii) 前記乳酸デヒドロゲナーゼ及び前記安定化剤を含む溶液を電極に塗布する工程、
iv)塗布した前記の溶液を乾燥させる工程、
を含む、前記方法。
[16] 乳酸デヒドロゲナーゼを塗布した電極が乳酸センサーに含まれる、15に記載の製造方法。
本開示に適用するLDHは、公知の野生型または変異型LDH同様、電子受容体存在下で乳酸の水酸基を酸化してピルビン酸を生成する反応を触媒する。なお、特に断らない限りLDHの基質は乳酸であり、これはL体及びD体の混合物、例えばラセミ体として提供されてもよく、又はL体として提供されてもよい。
LDHの活性は、この作用原理を利用し、例えば、図1に示すように電子受容体としてフェナジンメトサルフェート(PMS)および2,6-ジクロロインドフェノール(DCIP)を用いた以下の測定系を用いて測定することができる。
(反応1) L-乳酸 + PMS(酸化型)
→ ピルビン酸 + PMS(還元型)
(反応2) PMS(還元型) + DCIP(酸化型)
→ PMS(酸化型) + DCIP(還元型)
具体的には、LDHの活性は、以下の手順に従って測定することができる。1M リン酸カリウム緩衝液(pH7.5) 170μL、50mM L-乳酸溶液 300μLおよび1.8mM DCIP溶液 250μL、超純水680μLを混合し、37℃で2分間以上保温する。なお、L-乳酸としては、例えばSigma-Aldrich社製(製品番号L1750)を用いることができ、L-乳酸の代わりにDL-乳酸(例えば、富士フイルム和光純薬社製、製品番号128-00056)を用いることもできる。次いで、30mM PMS溶液 50μLおよび酵素サンプル溶液50μLを添加し、反応を開始する。反応開始時、および、経時的な吸光度を測定し、酵素反応の進行に伴う520nmにおける吸光度の1分間あたりの減少量(ΔA520)を求め、次式の数1に従い、LDH活性を算出する。この際、LDH活性は、37℃において濃度10mMのL-乳酸存在下で1分間に1μmolのDCIPを還元する酵素量を1Uと定義する。
LDHの熱安定性は、所定の温度で所定の時間だけLDHを加熱し、加熱前後の活性を比較することで評価することができる。具体的には、LDHを含んだ終濃度として0.15%(w/v) ウシ血清アルブミンを含む150mMリン酸カリウム緩衝液(pH7.5)を氷上に静置し、所定の温度(例えば45℃、50℃、55℃、60℃で有り得る)で15分間それぞれ加熱した後、LDH活性を測定する。加熱処理をせず、氷上に静置しておいたLDH溶液のLDH活性を100として加熱後のLDH溶液の活性を算出し、残存活性率(活性残存率)(%)を測定することができる。
本開示でいう「安定性の向上」とは、「溶液状態における熱安定性の向上」のみならず、「乾燥状態における熱安定性の向上」、または「乾燥工程における熱安定性の向上」、または「溶液状態における保存安定性(長期安定性)の向上」や、「乾燥状態における保存安定性(長期安定性)の向上」をも含む。
すなわち、本開示でいう「安定性が向上した」とは、LDHを含む組成物を、特定の安定化剤と共存させた状態において、一定の温度条件下、一定時間熱処理後、あるいは長期保存後に維持されているLDHの残存活性率(%)が、前記の安定化剤を共存させない場合と比較して増大していることをいう。
本開示の方法に適用することができる、LDHの由来は特に限定されず、原核生物由来、真核生物由来、微生物由来、真菌由来、植物由来、又は動物由来のものを使用し得る。本開示を適用し得るLDHはフラビン依存性であり、補酵素であるフラビン化合物はフラビンモノヌクレオチド(FMN)若しくはフラビンアデニンジヌクレオチド(FAD)で有り得る。
アミノ酸配列の同一性又は類似性は、GENETYX Ver.11(ゼネティックス社製)のマキシマムマッチングやサーチホモロジー等のプログラムまたはDNASIS Pro(日立ソリューションズ社製)のマキシマムマッチングやマルチプルアライメント等のプログラムにより計算することができる。アミノ酸配列同一性を計算するために、2以上のLDHをアライメントしたときに、該2以上のLDHにおいて同一であるアミノ酸の位置を調べることができる。こうした情報を基に、アミノ酸配列中の同一領域を決定できる。
蛋白質工学的手法を駆使する方法としては、一般的に、Site-Specific Mutagenesisとして知られる手法を用いることができる。例えば、Kramer法 (Nucleic Acids Res.,12,9441(1984):Methods Enzymol.,154,350(1987):Gene,37,73(1985))、Eckstein法(Nucleic Acids Res.,13,8749(1985):Nucleic Acids Res.,13,8765(1985):Nucleic Acids Res,14,9679(1986))、Kunkel法(Proc. Natl. Acid. Sci. U.S.A.,82,488(1985):Methods Enzymol.,154,367(1987))等が挙げられる。DNA中の塩基配列を変換する具体的な方法としては、例えば市販のキット(Transformer Mutagenesis Kit;Clonetech社, EXOIII/Mung Bean Deletion Kit;Stratagene製, Quick Change Site Directed Mutagenesis Kit;Stratagene製など)の利用が挙げられる。
LDHはさらに、機能性変異体を取得するためにハイスループットスクリーニングに供することができる。例えば変異導入したLDH遺伝子を有する形質転換又は形質導入株のライブラリーを作製し、これをマイクロタイタープレートに基づくハイスループットスクリーニングに供してもよく、または液滴型マイクロ流体に基づく超ハイスループットスクリーニングに供してもよい。例としてはバリアントをコードする変異遺伝子のコンビナトリアルライブラリーを構築し、次いでファージディスプレイ(例えばChem. Rev. 105 (11): 4056-72, 2005)、イーストディスプレイ(例えばComb Chem High Throughput Screen. 2008;11(2): 127-34)、バクテリアルディスプレイ(例えばCurr Opin Struct Biol 17: 474-80, 2007)等を用いて、変異LDHの大きな集団をスクリーニングする方法が挙げられる。またAgresti et al, "Ultrahigh-throughput screening in drop-based microfluidics for directed evolution" Proceedings of the National Academy of Sciences 107 (9): 4004-4009 (Mar, 2010)を参照のこと。アマドリアーLDHバリアントのスクリーニングに使用しうる超ハイスループットスクリーニング手法についての同文献の記載を参照により本明細書に組み入れる。例えばエラープローンPCR法によりライブラリーを構築することができる。また飽和突然変異誘発を用いて、本明細書に記載の位置又はそれに対応する位置を標的として変異導入しライブラリーを構築してもよい。ライブラリーを用いて電気コンピテントEBY-100細胞等の適当な細胞を形質転換し、約10の7乗の変異体を取得しうる(107)。これを10回繰り返せば約10の8乗の変異体を取得しうる(108)。該ライブラリーで形質転換した酵母細胞を次いでセルソーティングに供しうる。標準ソフトリトグラフィー法を用いて作製したポリジメトキシルシロキサン(PDMS)マイクロ流体デバイスを用いてもよい。フローフォーカスデバイスを用いて単分散の液滴を形成することができる。個別の変異体を含有する形成された液滴を適当なソーティングデバイスに供しうる。細胞を選別する際にはデヒドロゲナーゼ活性の有無を利用しうる。変異導入と選別は複数回反復してもよい。
本開示を適用し得るLDHは、公知文献に基づいて入手可能である。例えば、上記のLDHを生産する由来微生物を培養することにより、あるいは、天然のLDHをコードする遺伝子をそのまま、あるいは、変異させてから、適当な発現用ベクターに挿入し、適当な宿主(例えば大腸菌、酵母、麹菌)に形質転換させた形質転換体を培養し、培養液から遠心分離などで菌体を回収した後、該培養物よりLDHを採取する方法が挙げられる。
培地の初発pHは、限定されないが、例えば、pH6~9に調整することができる。
培養は、10~42℃の培養温度、好ましくは25℃前後の培養温度で4~24時間、さらに好ましくは25℃前後の培養温度で4~8時間、通気攪拌深部培養、振盪培養、静置培養等により実施すればよい。
本開示におけるLDHの濃度には特に制約がない。用いる酵素の特性等によって適切な範囲は異なるが、実用上、当該酵素を用いて乳酸を十分な信頼性をもって測定できると当業者が判断できる濃度であればよい。
例えば、本開示におけるLDHの濃度は特に制約がないが、溶液中の場合、好ましくは、0.01~1,000U/mL、さらに好ましくは、0.1~100U/mL、さらに好ましくは0.1~10U/mLである。粉末あるいは凍結乾燥物中でも同程度の濃度が望ましいが、粉末標品を調製する目的では、100U/mL以上の濃度にすることができる。
緩衝剤の濃度は、必要とされる緩衝能を有する範囲であれば特に限定されないが、好ましい上限は100mM以下、より好ましくは50mM以下である。好ましい下限は5mM以上である。粉末あるいは凍結乾燥物中においては緩衝剤の含有量は、特に限定されるものではないが、好ましくは0.1%(重量比)以上、特に好ましくは0.1~30%(重量比)の範囲で使用される。
i) LDHを用意する工程、
ii) LDHに35~70℃において熱処理を5~60分間行う工程、
iii) 前記ii)の後、LDHの残存活性を決定する工程、
iv) ii)においてLDH単独ではなく、代わりにLDHを候補物質の存在下で熱処理を行った後、LDHの残存活性を決定する工程、及び
v) 前記iii)における残存活性と、iv)における候補物質の存在下での残存活性とを比較する工程
を含み得る。前記iii)における残存活性よりも、iv)における候補物質の存在下での残存活性が増加している場合には、候補物質は、LDHの安定性を向上させる安定化剤とすることができる。
上述のようなLDHの安定性を向上させる各種の安定化剤を、LDHと共存させることにより、LDHの安定性が向上した組成物を製造することができる。本開示の酵素を含む組成物は凍結乾燥物に限られず、乾燥物を再溶解した溶液状態であってもよい。具体的には、本開示の組成物は、LDHと各種安定剤とを任意の方法で共存させればよい。例えば、両者が溶液状態である場合には、それを混合することにより組成物を製造することができ、両者が粉末状態である場合には粉末状態でそれらを混合することにより組成物を製造することができる。LDHを粉末化し、その後の造粒工程において安定化剤を添加することもできる。また、複数種の安定化剤を、一部はLDHの製造工程において共存させ、残りは乳酸測定試薬の調整段階や乳酸センサーへの固定化工程において共存させることもできる。
i) LDHを用意する工程、
ii) LDHに35~70℃において熱処理を5~60分間行う工程、
iii) 前記ii)の後、LDHの残存活性を決定する工程、
iv) ii)においてLDH単独ではなく、代わりにLDHを候補物質の存在下で熱処理を行った後、LDHの残存活性を決定する工程、
v) 前記iii)における残存活性と、iv)における候補物質の存在下での残存活性とを比較する工程、
vi) 前記iii)における残存活性よりも、iv)における候補物質の存在下での残存活性が増加している場合には、候補物質をLDHと共存させることにより、LDHの安定性が向上した組成物を製造する工程、
を含み得る。
i) 乳酸デヒドロゲナーゼを含む溶液を用意する工程、
ii)前記溶液に、モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩からなる群より選択されるアニオン、単糖、二糖、ポリエチレングリコール、及びイオン性ポリマーからなる群より選択される1以上の安定化剤を添加する工程、
iii) 前記乳酸デヒドロゲナーゼ及び前記安定化剤を含む溶液を電極に塗布する工程、
iv)塗布した前記の溶液を乾燥させる工程、
を含み得る。ある実施形態において、乳酸デヒドロゲナーゼを塗布した電極は乳酸センサーに含まれ得る。
ある実施形態では、LDHを電極に固定化して用いる場合、又はLDHを固定化することなく用いる場合、メディエータとして、公知のメディエータ、例えば1-メトキシ-5-メチルフェナジニウムメチルスルファート(mPMS)、5-メチルフェナジニウムメチルスルファート(PMS)、5-エチルフェナジニウムメチルスルファート(PES)等のフェナジン系化合物、フェノチアジン系化合物、フェリシアン化カリウム等のフェリシアン化物、フェロセン、ジメチルフェロセン、フェロセンカルボン酸等のフェロセン系化合物、ナフトキノン、アントラキノン、ヒドロキノン、ピロロキノリンキノン等のキノン系化合物、シトクロム系化合物、ベンジルビオロゲンやメチルビオロゲン等のビオロゲン系化合物、ジクロロフェノールインドフェノール等のインドフェノール系化合物、塩化ヘキサアンミンルテニウム等のルテニウム錯体、オスミウム-2,2’-ビピリジン等のオスミウム錯体、p-フェニレンジアミン、N-イソプロピル-N’-フェニル-p-フェニレンジアミン等のフェニレンジアミン系化合物を用いることができる。
本開示のLDHを含有する組成物を用いて、LDHの安定性が向上した乳酸測定用試薬、乳酸アッセイキット、乳酸センサーを製造することができ、これを用いて乳酸の測定を行うことができる。
本開示の乳酸アッセイキットには、典型的には、少なくとも1回の乳酸測定に十分な量のLDHと、アッセイに必要な緩衝液、メディエータ、キャリブレーションカーブ作製のための乳酸標準溶液を含み、LDHの安定性を向上させることに寄与する安定化剤を含む。本開示の乳酸アッセイキットは従来の乳酸アッセイキットと同様に用いて乳酸を測定することができ、本開示の乳酸アッセイキットを用いた場合には、LDHの安定性が向上していることから、本開示の乳酸アッセイ用キットは、より優れた熱安定性および保存安定性を示す。
ある実施形態において本開示はまた、LDHの熱安定性が向上している乳酸センサーを提供する。ある実施形態においてセンサーは電極を有する。ある実施形態においてセンサーは電極として作用極、対極を有する。ある実施形態においてセンサーは電極として作用極、対極及び参照極を有する。ある実施形態においてLDHは電極に固定化されている。作用極としては、カーボン電極、金電極、白金電極などを用い、この電極上に本開示の酵素を固定化することができる。固定化方法としては、架橋試薬を用いる方法、高分子マトリックス中に封入する方法、透析膜で被覆する方法、光架橋性ポリマー、導電性ポリマー、酸化還元ポリマーを用いる方法などがあり、あるいはメディエータとともにポリマー中に固定あるいは電極上に吸着固定してもよく、またこれらを組み合わせて用いてもよい。典型的には、グルタルアルデヒドを用いて本開示のLDHをカーボン電極上に固定化した後、アミン基を有する試薬で処理してグルタルアルデヒドをブロッキングする。本開示の安定化剤を含む組成物又は試薬は、LDHを固定化した電極、又は酵素センサー等と共に、ポテンショスタットやガルバノスタットなどを用いて、種々の電気化学的測定に用いることができる。電気化学的測定法としては、アンペロメトリー、例えばクロノアンペロメトリー、ポテンシャルステップ・クロノアンペロメトリー、ボルタンメトリー、例えばサイクリックボルタンメトリー、微分パルスボルタンメトリー、ポテンショメトリー、クーロメトリーなどの様々な手法が挙げられる。例えば乳酸測定では、アンペロメトリー法により、乳酸が還元される際の電流を測定することで、試料中の乳酸濃度を算出することができる。印加電圧は条件や装置の設定にもよるが、例えば-1,000mV~+1,000mV(vs. Ag/AgCl)などとすることができる。
ある実施形態において本開示は、熱安定性が向上しているLDH組成物を含むアノード電極を提供する。ある実施形態においてLDHは電池の有する電極に固定化されていてもよい。ある実施形態において、本開示のアノード電極はカソード電極と抵抗を組み合わせて電池を提供することができる。ある実施形態において本開示は、前記の電池を用いる発電方法を提供する。別の実施形態では、本開示の熱安定性が向上しているLDH組成物を含む電池が提供される。
ある実施形態において本開示は、燃料電池用のアノード又はカソード及び当該アノード又はカソードを備えた燃料電池を提供する。この燃料電池は本開示の熱安定性が向上しているLDH組成物を含む。ある実施形態において本開示は、前記の熱安定性が向上しているLDH組成物を含む電池を使用した発電方法、並びに、LDHをアノード電極に固定化し、LDHに対応した基質、例えば乳酸を燃料とし、発電を行う方法を提供する。
各種組換え体プラスミドの調製
Biochem. J. 258, 255-259(1989)に記載されているように、Saccharomyces cereviciae由来乳酸デヒドロゲナーゼ(ScLDH)のアミノ酸配列である591アミノ酸のうち、1~85位のアミノ酸を除去した配列番号1に示す506アミノ酸をコードする配列番号2で示される1521bpの遺伝子(終止コドンTAAを含む)を、定法である遺伝子断片のPCRにより、2本鎖DNAとして取得した。プラスミドpKK223-3のマルチクローニングサイトに対象遺伝子であるScLDH遺伝子を常法により挿入させたDNAコンストラクトを作製した。具体的には、pKK223-3のマルチクローニングサイトにあるIn-Fusion Cloning Siteにて、ScLDH遺伝子を、In-Fusion HD Cloning Kit(クロンテック社製)を使用して、キットに添付されたプロトコールに従って連結して、発現用プラスミド(pKK223-3-ScLDH)を得た。さらにこれらのプラスミドを用いて大腸菌JM109を形質転換し、大腸菌JM109(pKK223-3-ScLDH)株を、3mLのLB-amp培地[1%(w/v)バクトトリプトン、0.5%(w/v)ペプトン、0.5%(w/v)NaCl、50μg/mL アンピシリン]に接種して、37℃で16時間振とう培養し、培養物を得た。この培養物を10,000×gで、1分間遠心分離することにより集菌して菌体を得た。この菌体より、GenElute Plasmid Miniprep Kit(Sigma-Aldrich社製)を用いて組換え体プラスミドpKK223-3-ScLDHを得た。
LDH生産菌として、大腸菌BL21株を用いた。まず、pKK223-3-ScLDHを形質導入した大腸菌BL21(pKK223-3-ScLDH)株は予めLBプレート培地(100μg/mL アンピシリン入り)上で培養した株のコロニーをつまようじでつつき、LB培地2mL(100μg/mL アンピシリン入り)を入れた小試験管で、25℃、160rpmで24時間振とう培養した。この培養液全量を、LB培地250mL(50μg/mL アンピシリン、1mM イソプロピル-β-チオガラクトピラノシド(以下IPTG)入り)を入れた0.5L容坂口フラスコに移し、25℃、130rpmで30時間振とう培養した。同様にして、pKK223-3-PkLDHを形質導入した大腸菌BL21(pKK223-3-PkLDH)株を、LB培地2mL(100μg/mL アンピシリン)を入れた小試験管で、30℃、160rpmで終夜振とう培養した。この培養液全量を、LB培地250mL(50μg/mL アンピシリン、1mM IPTG入り)を入れた0.5L容坂口フラスコに移し、37℃、130rpmで30時間振とう培養した。同様にして、pKK223-3-CaLDH若しくはpKK223-3-OgLDHを形質導入した大腸菌BL21(pKK223-3-CaLDH)株、大腸菌BL21(pKK223-3-OgLDH)株を、LB培地2mL(100μg/mL アンピシリン)を入れた小試験管で、30℃、160rpmで終夜振とう培養した。この培養液全量を、LB培地250mL(50μg/mL アンピシリン、1mM IPTG入り)を入れた0.5L容坂口フラスコに移し、30℃、130rpmで30時間振とう培養した。
上記の菌体懸濁液を、超音波ホモジナイザーUS-150E(日本精機製作所製)を用いて、懸濁液が半透明になるまで超音波破砕を行い、9,000rpm、4℃で10分遠心して上清を回収した。ScLDHを除く各種LDHを含む菌体破砕液の上清について、陰イオン交換クロマトグラフィー精製を行った。具体的にはまず、20mM リン酸カリウム緩衝液 (pH 7.5)を用いて平衡化した10mLのQ Sepharose Fast Flow (Cytiva社製)に対し、各種LDHを含む上清液を樹脂に添加した。次に、0~500mM NaClを含む20mM リン酸カリウム緩衝液(pH 7.5)を添加し、LDH活性が高い画分を回収した。得られたLDH活性を示す画分をAmicon(登録商標) Ultra-15 Centrifugal Filters Ultracel(登録商標)-30Kを用いて濃縮した。続いて、Hiscreen Capto Q ImpRes カラム(Cytiva社製)に吸着させ、PkLDHは250mMから450mM NaCl/20mM リン酸カリウム緩衝液(pH7.0)のグラディエントによりLDH活性を示す画分を回収した。CaLDH、OgLDHの精製においては、150mMから350mM NaCl/20mM リン酸カリウム緩衝液(pH7.0)までのグラディエントによりLDH活性を示す画分を回収した。続いて、回収した画分をそれぞれ、150mM塩化ナトリウムを含む10mM リン酸カリウム緩衝液(PkLDHはpH7.0、CaLDH、OgLDHはpH7.5)で平衡化したHiLoad 26/600 Superdex 200 pgカラム(Cytiva社製)に供し、得られた画分をSDS-PAGEにより分析し、単一なバンドを示し、かつ、LDH活性を示す画分を回収し、各種LDHの精製標品とした。
上記で取得したPkLDH精製標品を用いて、前述のLDHの熱安定性の評価方法に準じて、LDHの安定化剤の添加有無における残存活性率(%)を比較することで、安定化剤の探索を行った。
LDHの熱安定性は、所定の温度で所定の時間だけLDHを加熱し、加熱前後の活性を比較することで評価した。具体的には、LDHを含んだ終濃度として0.15%(w/v) ウシ血清アルブミンを含む150mMリン酸カリウム緩衝液(pH7.5)を氷上に静置し、所定の温度(例えば45℃、50℃、55℃、60℃で有り得る)で15分間それぞれ加熱した後、LDH活性を測定した。また、加熱処理をせず、氷上に静置しておいたLDH溶液のLDH活性を測定し、その活性を100として加熱後のLDH溶液の活性を算出し、残存活性率(%)を測定した。具体的には、残存活性率(%)は、熱処理前あるいは長期保存前の溶液のLDH活性値(a)と、熱処理後あるいは長期保存後のLDH活性値(b)をそれぞれ測定し、((b)/(a)×100)を計算することによって算出した。
種々の化合物を添加することによるLDHの安定性向上効果の程度は、種々の化合物をLDHとそれぞれ共存させた状態でLDH溶液を調製し、加熱処理に供してそれぞれの残存活性率(%)を測定し、それを、化合物同士で、あるいは、化合物を添加しない場合の活性残存率(%)と比較することにより評価した。
LDHの活性は、以下の手順に従って測定した。1M リン酸カリウム緩衝液(pH7.5) 170μL、50mM DL-乳酸(富士フイルム和光純薬社製、製品番号128-00056)溶液 300μLおよび1.8mM DCIP溶液 250μL、超純水680μLを混合し、37℃で2分間以上保温した。次いで、30mM PMS溶液 50μLおよび酵素サンプル溶液50μLを添加し、反応を開始した。反応開始時、および、経時的な吸光度を測定し、酵素反応の進行に伴う520nmにおける吸光度の1分間あたりの減少量(ΔA520)を求め、次式の数2に従い、LDH活性を算出した。この際、LDH活性は、37℃において濃度10mMのL-乳酸存在下で1分間に1μmolのDCIPを還元する酵素量を1Uと定義した。
特に、硫酸アンモニウム、L-リンゴ酸、グルコン酸ナトリウム、コハク酸、L-アスパラギン酸ナトリウム、L-グルタミン酸、L-アルギニン塩酸塩を添加した場合には、安定化剤添加無しのPkLDHの活性残存率(%)が30%であるのに対し、活性残存率(%)が50%以上となった。つまり、これらの安定化剤によるLDHの安定性向上効果は20%以上となり、高い安定性向上効果が確認された。特に、L-リンゴ酸を添加した際には、LDHの活性残存率(%)は78%となった。すなわち、L-リンゴ酸によるLDHの安定性は大幅に向上し、顕著に高い安定性向上効果が明らかとなった。
L-リンゴ酸と構造が類似している化合物についても同様に、上記4.に記載の方法に従い、安定性評価試験を行った。比較例として、各種化合物を添加せずに調製したPkLDH溶液(pHを7.5に調整した150mMリン酸カリウム緩衝液、0.15%(w/v) BSAを含む)を用いた場合でも、同様に試験を行った。L-リンゴ酸類似化合物としては表2に示すように、D-リンゴ酸、DL-ロイシン酸、DL-3-ヒドロキシアスパラギン酸、DL-3-フェニル乳酸、オキサロ酢酸、D-(-)-酒石酸、L-(+)-酒石酸を添加した。
これらの検討の結果、表2に示す通り、D-リンゴ酸、DL-3-ヒドロキシアスパラギン酸、オキサロ酢酸、D-(-)-酒石酸、L-(+)-酒石酸を添加した時にLDHの安定性が向上することが明らかとなった。特に、DL-3-ヒドロキシアスパラギン酸、D-(-)-酒石酸、L-(+)-酒石酸を添加した場合には、化合物添加なしの活性残存率(%)が30%であるのに対し、活性残存率(%)が50%を越え、高い安定性が確認された。それらの中でも、DL-3-ヒドロキシアスパラギン酸、DL-ロイシン酸、DL-フェニル乳酸は活性残存率(%)がそれぞれ77%、92%、87%となった。つまり、DL-3-ヒドロキシアスパラギン酸、DL-ロイシン酸、DL-フェニル乳酸を添加することによって、顕著に高いLDHの安定性向上効果が明らかとなった。
種々のLDHに対するリンゴ酸の安定性向上効果に関しての安定性評価試験を行った。上記で取得したLDH標品(PkLDH、CaLDH、OgLDH)を、各々、酵素濃度が2U/mLとなるように、酵素希釈液(150mM リン酸カリウム緩衝液中、終濃度300mMとなるようL-リンゴ酸を添加し、NaOHを用いてpH7.5に調整した後、終濃度0.15%(w/v)となるようウシ血清アルブミンを添加して調製)を用いて希釈した。このそれぞれの希釈された酵素溶液(酵素とL-リンゴ酸の混合組成物、LDH濃度:2U/mL、L-リンゴ酸濃度:300mM)を用いて、上記4.に記載の熱安定性の評価方法に従い、PkLDHは55℃で、CaLDHとOgLDHは50℃で15分加熱処理後の活性残存率(%)を、加熱前の活性を100として算出した。比較例として、酵素希釈液中にL-リンゴ酸を添加しないものについて、同様の試験を行い、両者の活性残存率を比較した。
その結果、表3に示す通り、3種のLDH全てにおいて、L-リンゴ酸を添加することによってLDHの安定性が向上することが確認された。
リンゴ酸添加による安定化効果の濃度依存性を調べた。上記で取得したLDH標品(PkLDH)を、酵素濃度が2U/mLとなるように、酵素希釈液(150mM リン酸カリウム緩衝液中、終濃度10mM、30mM、100mM、300mM、500mMとなるようL-リンゴ酸を添加し、NaOHを用いてpH7.5に調整した後、終濃度0.15%(w/v)となるようウシ血清アルブミンを添加して調製)を用いて希釈した。この希釈された酵素溶液(酵素とL-リンゴ酸の混合組成物、LDH濃度:2U/mL、L-リンゴ酸濃度:10mM、30mM、100mM、300mM、500mM)について、上記4.に記載の方法に従って55℃で15分加熱処理した。加熱処理後の活性残存率(%)を、加熱前の活性を100として算出した。
その結果、表4に示す通り、添加するリンゴ酸の濃度を高めることにより、LDHの安定性が向上する傾向が確認された。
上記で取得したCaLDH精製標品を用いて、上記4.に記載のLDHの熱安定性の評価方法に従い、LDHの安定化剤の添加有無における残存活性率を比較することで、安定化剤の探索を行った。
150mMのリン酸カリウム緩衝液、300mMの各種化合物(マルトース一水和物、エチレンジアミン四酢酸)と0.15%(w/v)ウシ血清アルブミン(BSA)を含むLDH溶液(2U/mL)を用いて、LDHの残存活性率を算出した。前記の各種LDH溶液は、各種化合物をそれぞれ添加した後にpH7.5となるよう調整を行った。加熱処理は50℃、15分間行った。比較例として、各種化合物を添加せずに調製したLDH溶液(pHを7.5に調整した150mMリン酸カリウム緩衝液、0.15%(w/v) BSAを含む)を用いた場合でも、同様に試験を行った。
その結果、マルトース一水和物によるLDHの安定性向上効果は5%であり、エチレンジアミン四酢酸によるLDHの安定性向上効果は56%であった。すなわち、マルトース一水和物やエチレンジアミン四酢酸を添加することにより、LDHの熱安定性が向上することが明らかとなった。
上記で取得したOgLDH精製標品を用いて、上記4.に記載のLDHの熱安定性の評価方法に従い、LDHの安定化剤の添加有無における残存活性率を比較することで、安定化剤の探索を行った。
150mMのリン酸カリウム緩衝液、300mMの各種化合物(グリシン、L-リジン塩酸塩、L-ヒスチジン、マロン酸二ナトリウム)と0.15%(w/v)BSAを含むLDH溶液(2U/mL)を用いて、LDHの残存活性率を算出した。前記の各種LDH溶液は、各種化合物をそれぞれ添加した後にpH7.5となるよう調整を行った。加熱処理は50℃、15分間行った。比較例として、各種化合物を添加せずに調製したLDH溶液(pHを7.5に調整した150mMリン酸カリウム緩衝液、0.15%(w/v) BSAを含む)を用いた場合でも、同様に試験を行った。
その結果、グリシンによるLDHの安定性向上効果は11%、L-リジン塩酸塩によるLDHの安定性向上効果は66%、L-ヒスチジンによるLDHの安定性向上効果は27%、マロン酸二ナトリウムによるLDHの安定性向上効果は96%であった。つまり、グリシン、L-リジン塩酸塩、L-ヒスチジンやマロン酸二ナトリウムを添加することにより、LDHの熱安定性が向上することが明らかとなった。その中でも特に、マロン酸二ナトリウムのLDHの安定性向上効果が高かった。
上記で取得したScLDHの菌体破砕液上清を用いて、上記4.に記載のLDHの熱安定性の評価方法に従い、LDHの安定化剤の添加有無における残存活性率を比較することで、安定化剤の探索を行った。
150mMのリン酸カリウム緩衝液、300mMの各種化合物(L-リンゴ酸、マロン酸二ナトリウム、硫酸アンモニウム)と0.15%(w/v)BSAを含むLDH溶液(2U/mL)を用いて、LDHの残存活性率を算出した。前記の各種LDH溶液は、各種化合物をそれぞれ添加した後にpH7.5となるよう調整を行った。加熱処理は40℃、15分間行った。比較例として、各種化合物を添加せずに調製したLDH溶液(pHを7.5に調整した150mMリン酸カリウム緩衝液、0.15%(w/v) BSAを含む)を用いた場合でも、同様に試験を行った。
その結果、L-リンゴ酸によるScLDHの安定性向上効果は41%、マロン酸二ナトリウムによるScLDHの安定性向上効果は26%、硫酸アンモニウムによるLDHの安定性向上効果は24%であった。つまり、PkLDH、CaLDH、OgLDHと同様にScLDHもL-リンゴ酸やマロン酸二ナトリウム、硫酸アンモニウムを添加することで熱安定性が向上することが明らかとなった。
上記で取得したPkLDH精製標品を用いて、さらに同様に、上記4.に記載のLDHの熱安定性の評価方法に準じて、安定化剤の探索を行った。ただし緩衝液をリン酸カリウム緩衝液から、150mMのHEPES緩衝液に変えて実施した。表5記載の300mMの各種化合物と0.15%(w/v) ウシ血清アルブミン(BSA)を含む、LDH溶液(2U/mL)を用いて、上記の熱安定性の評価方法に従いLDHの残存活性率を算出した。ただし、ポリエチレングリコール、ポリリジンの場合のみ、終濃度を2%となるよう添加した。前記の各種LDH溶液は、各種化合物をそれぞれ添加した後にpH7.5となるよう調整を行った。加熱処理は55℃、15分間行った。比較例として、各種化合物を添加せずに調製したLDH溶液(pHを7.5に調整した150mM HEPES緩衝液、0.15%(w/v) BSAを含む)を用いた場合でも、同様に試験を行った。
その結果、リン酸カリウム、ポリエチレングリコール、εポリリジンを添加した時にLDHの安定性が向上することが明らかとなった(表5)。特に、リン酸カリウム、ポリリジンを添加した場合には、化合物添加なしの活性残存率(%)が27%であるのに対し、活性残存率(%)が70%を越え、顕著に高い安定性が確認された。また、L-リンゴ酸やマロン酸二ナトリウムのようなこれまで見出した安定化剤は、リン酸緩衝液中だけではなくHEPES緩衝液に添加した場合においても安定化効果を発揮し、緩衝液の種類によらず安定化剤として有効であることがわかった。このことから、上記で見出した各種の安定化向上に寄与する化合物が、緩衝液の種類によらず効果を奏しうることが示唆される。
上記で取得したPkLDH精製標品を用いて、さらに同様に、上記4.に記載のLDHの熱安定性の評価方法に準じて、安定化剤の探索を行った。表6記載の2%(w/v)の各種化合物と0.15%(w/v) ウシ血清アルブミン(BSA)を含む、LDH溶液(3U/mL)を用いて、上記の熱安定性の評価方法に従いLDHの残存活性率を算出した。前記の各種LDH溶液は、各種化合物をそれぞれ添加した後にpH7.5となるよう調整を行った。加熱処理は55℃、15分間行った。比較例として、各種化合物を添加せずに調製したLDH溶液(pHを7.5に調整した150mM リン酸カリウム緩衝液、0.15%(w/v) BSAを含む)を用いた場合でも、同様に試験を行った。
上記で取得したPkLDH精製標品を用いて、さらに同様に、上記4.に記載のLDHの熱安定性の評価方法に準じて、安定化剤の探索を行った。表7記載の質量パーセント濃度またはモル濃度の各種化合物と0.15%(w/v) ウシ血清アルブミン(BSA)を含む、LDH溶液(3U/mL)を用いて、上記の熱安定性の評価方法に従いLDHの残存活性率を算出した。前記の各種LDH溶液は、各種ポリマー化合物をそれぞれ添加した後にpH7.5となるよう調整を行った。加熱処理は55℃、15分間行った。比較例として、各種化合物を添加せずに調製したLDH溶液(pHを7.5に調整した150mM リン酸カリウム緩衝液、0.15%(w/v) BSAを含む)を用いた場合でも、同様に試験を行った。
上記で取得したPkLDH精製標品を用いて酵素電極を作製し、クロノアンペロメトリ測定を行った。各種化合物を酵素溶液に予め添加することによって、乾燥工程において酵素の安定化効果がみられるか検討した。表8記載の濃度(0.2%(w/v)、2%(w/v)または50mM)の各種化合物を含む1UのLDH溶液をスクリーン印刷カーボン電極C110(Metrohm-Dropsens社製)に4μL塗布し、40℃、60分間乾燥させた。各種化合物を添加せずに調製したLDH溶液を用いた場合でも、同様に行った。作製した電極は専用コネクター(Drop Sense社製、DRP-CAC)を用いて、ALS 電気化学アナライザー 814D(BAS社製)に接続した。次に、100μLの2mM mPMS/PBS溶液を滴下し、乾燥させたLDHを溶解させた。印加電圧は+200mV(vs Ag/Ag+)とした。L-乳酸ナトリウム溶液を添加し、測定開始から5秒後の応答電流値を記録した。その結果、表8に示す通り、いずれの化合物を添加した場合に、化合物を添加しなかった場合と比較して電流値が大きくなった。また、上記と同様にして、1%ポリアクリル酸を含む1UのLDH溶液をスクリーン印刷カーボン電極に塗布、乾燥させ、100μLの2mM mPMS/PBS溶液を滴下し、乾燥させたLDHを溶解させた。終濃度2~10mMとなるようにL-乳酸ナトリウム溶液を添加し、測定開始から5秒後の応答電流値を記録した。その結果、終濃度10mM L-乳酸ナトリウム添加時の電流値は20μAであった。ポリアクリル酸を添加しなかった際の電流値は、14μAであり、ポリアクリル酸を添加した方が高い電流値であった。また、終濃度2~10mM L-乳酸ナトリウム添加時の電流値を縦軸、乳酸濃度を横軸にしたグラフを作製した際の直線性はR2=0.97であり、L-乳酸を定量できることが示された。この結果から、液状試験での結果で効果があった化合物は、電極を作製する際の乾燥工程において酵素の失活を抑制でき、酵素の安定化効果を発揮することが示唆された。
安定化剤として添加する化合物、および基質として用いるL-乳酸ナトリウムの濃度を変えて、前項で行ったクロノアンペロメトリ測定の実験を行った。前項と同様の手順で作成した電極に100μLの5mM mPMS/PBS溶液を滴下し、乾燥させたLDHを溶解させた。印加電圧は+200mV(vs Ag/Ag+)とした。L-乳酸ナトリウム溶液を添加し、測定開始から5秒後の応答電流値を記録した。その結果、表9に示す通り、リンゴ酸ナトリウムやmyo-イノシトールを添加した場合にも、化合物を添加しなかった場合と比較して電流値が大きくなった。また、添加するポリマーの濃度を希釈しても化合物を添加しなかった場合と比較して電流値が大きくなった。さらに、これまでに安定性向上効果が見られた化合物は乳酸濃度が0~10mMのいずれの範囲において用いても同様に安定性向上効果を示した。この結果から、液状試験での結果で効果があった化合物は、電極を作製する際の乾燥工程において、その濃度によらず、酵素の失活を抑制でき、酵素の安定化効果を発揮することが示された。また、LDHが電極上で0~10mMの乳酸と反応する際に添加した化合物と共存していても、十分に活性を示すことが明らかとなった。
配列番号1 Saccharomyces cereviciae由来乳酸デヒドロゲナーゼ(ScLDH)(ただし野生型の1~85位は除去)
配列番号2 配列番号1のアミノ酸配列をコードする塩基配列
配列番号3 Pichia kudriavzevii由来乳酸デヒドロゲナーゼ(PkLDH)のアミノ酸配列
配列番号4 配列番号3の2~77位の配列を除去した配列
配列番号5 配列番号4のアミノ酸配列をコードする塩基配列
配列番号6 Candida inconspicua由来乳酸デヒドロゲナーゼ(CaLDH)のアミノ酸配列
配列番号7 配列番号6の2~67位を除去した配列
配列番号8 配列番号7のアミノ酸配列をコードする塩基配列
配列番号9 Ogataea parapolymorpha由来乳酸デヒドロゲナーゼ(OgLDH)のアミノ酸配列
配列番号10 配列番号9の2~56位を除去した配列
配列番号11 配列番号10のアミノ酸配列をコードする塩基配列
Claims (16)
- フラビン化合物を補酵素とする乳酸デヒドロゲナーゼを含む組成物に、モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩(硫酸アンモニウムを除く)からなる群より選択されるアニオン、単糖、二糖、ポリエチレングリコール、若しくはイオン性ポリマーを1種類以上共存させる工程を含む、乳酸デヒドロゲナーゼ含有組成物の熱安定性を向上させる方法。
- 乳酸デヒドロゲナーゼが、サッカロマイセス属、ピキア属、カンディダ属、オガタエア属、ブレタノマイセス属、シベルリンドネラ属、ハンセニアスポラ属、カザツタニア属、クルイウェロマイセス属、ラチャンセア属、ナウモヴォジマ属、テトラピシスポラ属、トルラスポラ属、ヴァンデルワルトジマ属、ジゴサッカロマイセス属、ジゴトルラスポラ属、ミセリオフトラ属、サーモセロマイセエス属、カエトミウム属、又はマドゥレラ属由来の乳酸デヒドロゲナーゼである、請求項1に記載の方法。
- 乳酸デヒドロゲナーゼが以下の(i)及び/または(ii)である、請求項1に記載の乳酸デヒドロゲナーゼ含有組成物の熱安定性を向上させる方法、
(i)配列番号1、配列番号4、配列番号7、又は配列番号10に示されるアミノ酸配列との同一性が70%以上又は80%以上のアミノ酸配列を有する乳酸デヒドロゲナーゼ、
(ii)配列番号4の第138~140位、186~194位、217~222位、243~245位、271~278位、280~283位、355~367位、398~401位、403~406位及び425~433位のアミノ酸配列からなる相同性領域におけるアミノ酸配列と当該乳酸デヒドロゲナーゼの対応する位置の相同性領域におけるアミノ酸配列とが80%以上又は90%以上の配列同一性を有する乳酸デヒドロゲナーゼ。 - モノカルボン酸がグルコン酸、ロイシン酸、3-フェニル乳酸、グリシン、リジン、ヒスチジン及びアルギニンからなる群より選択され、
ジカルボン酸がリンゴ酸、コハク酸、マレイン酸、フマル酸、マロン酸、メチルマロン酸、オキサロ酢酸、酒石酸、シュウ酸、スクシン酸、グルタル酸、α-ケトグルタル酸、アジピン酸、ピメリン酸、スベリン酸、アゼライン酸、セバシン酸、フタル酸、イソフタル酸、テレフタル酸、グルタコン酸、タルトロン酸、ムコン酸、メサコン酸、シトラコン酸、メコン酸、3-3’ジメチルグルタル酸、イタコン酸、グルタミン酸、アスパラギン酸、及び3-ヒドロキシアスパラギンからなる群より選択され、
トリカルボン酸がクエン酸、イソクエン酸、アコニット酸、トリメシン酸、1,2,3-プロパントリカルボン酸、及び2-ホスホノブタン-1,2,4-トリカルボン酸からなる群より選択され、
テトラカルボン酸がエチレンジアミン四酢酸から選択され、
リン酸がリン酸塩及びピロリン酸塩からなる群より選択され、
硫酸が硫酸塩から選択され、
単糖がmyo-イノシトールからなる群より選択され、
二糖がスクロース、トレハロース、及びマルトースからなる群より選択され、又は
ポリエチレングリコール、
イオン性ポリマーがアニオン性ポリマーであるか、若しくはカチオン性ポリマーであり、
アニオン性ポリマーがポリアクリル酸、ヒアルロン酸、及びカルボキシメチルセルロース若しくはこれらの塩からなる群より選択されるか、若しくは、
カチオン性ポリマーがポリリジン、ポリエチレンイミン、メチルグリコールキトサン、及びポリ(塩化ジアリルジメチルアンモニウム)から選択される、請求項1~3のいずれかに記載の乳酸デヒドロゲナーゼ含有組成物の熱安定性を向上させる方法。 - モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩からなる群より選択されるアニオン、単糖、二糖、アニオン性ポリマー若しくはカチオン性ポリマーが溶液中において、0.01重量%から30重量%の範囲で含む、請求項1~4のいずれかに記載の乳酸デヒドロゲナーゼ含有組成物の熱安定性を向上させる方法。
- フラビン化合物を補酵素とする乳酸デヒドロゲナーゼ及び、モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩(硫酸アンモニウムを除く)からなる群より選択されるアニオン、単糖、二糖、ポリエチレングリコール、イオン性ポリマーのいずれか1種類以上の化合物を含む乳酸測定用組成物。
- 乳酸デヒドロゲナーゼが、サッカロマイセス属、ピキア属、カンディダ属、オガタエア属、ブレタノマイセス属、シベルリンドネラ属、ハンセニアスポラ属、カザツタニア属、クルイウェロマイセス属、ラチャンセア属、ナウモヴォジマ属、テトラピシスポラ属、トルラスポラ属、ヴァンデルワルトジマ属、ジゴサッカロマイセス属、ジゴトルラスポラ属、ミセリオフトラ属、サーモセロマイセエス属、カエトミウム属、又はマドゥレラ属由来の乳酸デヒドロゲナーゼである、請求項6に記載の乳酸測定用組成物。
- 乳酸デヒドロゲナーゼが以下の(i)及び/または(ii)である、請求項6に記載の組成物、
(i)配列番号1、配列番号4、配列番号7、又は配列番号10に示されるアミノ酸配列との同一性が70%以上又は80%以上のアミノ酸配列を有する乳酸デヒドロゲナーゼ、
(ii)配列番号4の第138~140位、186~194位、217~222位、243~245位、271~278位、280~283位、355~367位、398~401位、403~406位及び425~433位のアミノ酸配列からなる相同性領域におけるアミノ酸配列と当該乳酸デヒドロゲナーゼの対応する位置の相同性領域におけるアミノ酸配列とが80%以上又は90%以上の配列同一性を有する乳酸デヒドロゲナーゼ。 - モノカルボン酸がグルコン酸、ロイシン酸、3-フェニル乳酸、グリシン、リジン、ヒスチジン及びアルギニンからなる群より選択され、
ジカルボン酸がリンゴ酸、コハク酸、マレイン酸、フマル酸、マロン酸、メチルマロン酸、オキサロ酢酸、酒石酸、シュウ酸、スクシン酸、グルタル酸、α-ケトグルタル酸、アジピン酸、ピメリン酸、スベリン酸、アゼライン酸、セバシン酸、フタル酸、イソフタル酸、テレフタル酸、グルタコン酸、タルトロン酸、ムコン酸、メサコン酸、シトラコン酸、メコン酸、3-3’ジメチルグルタル酸、イタコン酸、グルタミン酸、アスパラギン酸、及び3-ヒドロキシアスパラギンからなる群より選択され、
トリカルボン酸がクエン酸、イソクエン酸、アコニット酸、トリメシン酸、1,2,3-プロパントリカルボン酸、及び2-ホスホノブタン-1,2,4-トリカルボン酸からなる群より選択され、
テトラカルボン酸がエチレンジアミン四酢酸から選択され、
リン酸がリン酸塩及びピロリン酸塩からなる群より選択され、
硫酸が硫酸塩から選択され、
単糖がmyo-イノシトールからなる群より選択され、
二糖がスクロース、トレハロース、及びマルトースからなる群より選択され、又は
ポリエチレングリコール、
イオン性ポリマーがアニオン性ポリマーであるか、若しくはカチオン性ポリマーであり、
アニオン性ポリマーがポリアクリル酸、ヒアルロン酸、及びカルボキシメチルセルロース若しくはこれらの塩からなる群より選択され、
カチオン性ポリマーがポリリジン、ポリエチレンイミン、メチルグリコールキトサン、及びポリ(塩化ジアリルジメチルアンモニウム)から選択される、請求項6~8のいずれかに記載の乳酸測定用組成物。 - モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩(硫酸アンモニウムを除く)からなる群より選択されるアニオン、単糖、二糖、ポリエチレングリコール若しくはアニオン性ポリマー又はカチオン性ポリマーが溶液中において、0.01重量%から30重量%の範囲で含む、請求項6~9のいずれかに記載の乳酸測定用組成物。
- 請求項6~10のいずれかに記載の組成物を含む乳酸測定用キット。
- フラビン化合物を補酵素とする乳酸デヒドロゲナーゼ及び、モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩からなる群より選択されるアニオン、単糖、二糖、ポリエチレングリコール、イオン性ポリマーのいずれか1種類以上の化合物を含む組成物を含む電極。
- 請求項12に記載の電極を含む乳酸センサー。
- 請求項12に記載の電極を含む燃料電池。
- 乳酸デヒドロゲナーゼを電極に塗布する工程を含む電極の製造方法において、乳酸デヒドロゲナーゼの活性低下又は失活を抑制する方法であって、
i) 乳酸デヒドロゲナーゼを含む溶液を用意する工程、
ii)前記溶液に、モノカルボン酸、ジカルボン酸、トリカルボン酸、テトラカルボン酸、ポリカルボン酸、リン酸、硫酸またはこれらの塩からなる群より選択されるアニオン、単糖、二糖、ポリエチレングリコール、イオン性ポリマーからなる群より選択される1以上の安定化剤を添加する工程、
iii) 前記乳酸デヒドロゲナーゼ及び前記安定化剤を含む溶液を電極に塗布する工程、
iv)塗布した前記の溶液を乾燥させる工程、
を含む、前記方法。 - 乳酸デヒドロゲナーゼを塗布した電極が乳酸センサーに含まれる、請求項15に記載の製造方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21875715.1A EP4223884A1 (en) | 2020-09-29 | 2021-09-29 | Method for improving stability of composition containing flavin-dependent lactate dehydrogenase |
KR1020237011749A KR20230078697A (ko) | 2020-09-29 | 2021-09-29 | 플라빈 의존성 락트산 데히드로게나제를 포함하는 조성물의 안정성을 향상시키는 방법 |
JP2022554051A JPWO2022071417A1 (ja) | 2020-09-29 | 2021-09-29 | |
US18/246,060 US20230365959A1 (en) | 2020-09-29 | 2021-09-29 | Method for improving the stability of a composition comprising a flavin-dependent lactate dehydrogenase |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-163631 | 2020-09-29 | ||
JP2020163631 | 2020-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022071417A1 true WO2022071417A1 (ja) | 2022-04-07 |
Family
ID=80950645
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/035929 WO2022071417A1 (ja) | 2020-09-29 | 2021-09-29 | フラビン依存性乳酸デヒドロゲナーゼを含む組成物の安定性を向上する方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20230365959A1 (ja) |
EP (1) | EP4223884A1 (ja) |
JP (1) | JPWO2022071417A1 (ja) |
KR (1) | KR20230078697A (ja) |
WO (1) | WO2022071417A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4108678A4 (en) * | 2020-02-21 | 2024-03-27 | Kikkoman Corporation | DEVICE FOR EVALUATION OF THE CONDITION OF A SAMPLE, SYSTEM COMPRISING SAME, METHOD FOR EVALUATION OF THE CONDITION OF A SAMPLE AND LACTATE DEHYDROGENASE USED FOR THIS PURPOSE |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58175498A (ja) * | 1982-03-26 | 1983-10-14 | メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 液体中の物質の測定用試験系および試験方法 |
JPS61159164A (ja) * | 1984-09-21 | 1986-07-18 | ジヨナサン・エル・キ−ル | ミクロ化学発光アツセイシステム |
JPH01104172A (ja) * | 1987-10-16 | 1989-04-21 | Agency Of Ind Science & Technol | 酵素の安定化法 |
JPH034791A (ja) * | 1989-05-30 | 1991-01-10 | Kanebo Ltd | 酵素の安定化方法 |
JPH04271785A (ja) * | 1991-02-28 | 1992-09-28 | Kao Corp | 酵素固形製剤及びその製造方法 |
JPH1169973A (ja) * | 1997-08-29 | 1999-03-16 | Kao Corp | 酵素の安定化方法 |
JP2000513940A (ja) * | 1996-07-03 | 2000-10-24 | モレキュラー バイオロジー リソーシス,インコーポレイテッド | 酵素の安定化のための方法および処方物 |
JP2007129965A (ja) * | 2005-11-11 | 2007-05-31 | Toyobo Co Ltd | 可溶性補酵素結合型のグルコースデヒドロゲナーゼ(gdh)を含む組成物の熱安定性を向上する方法 |
JP2007163268A (ja) * | 2005-12-13 | 2007-06-28 | Canon Inc | 酵素電極 |
JP2008154573A (ja) * | 2006-03-31 | 2008-07-10 | Toyobo Co Ltd | 可溶性グルコースデヒドロゲナーゼ(gdh)を含む組成物の安定性を向上する方法 |
JP2009034095A (ja) * | 2007-07-06 | 2009-02-19 | Sanyo Chem Ind Ltd | タンパク質含有水溶液安定化剤、タンパク質含有水溶液の安定化方法及びタンパク質含有水溶液 |
JP2012099242A (ja) * | 2010-10-29 | 2012-05-24 | Toyota Motor Corp | 酵素燃料電池 |
JP2014018096A (ja) * | 2012-07-13 | 2014-02-03 | Kikkoman Corp | フラビン結合型グルコースデヒドロゲナーゼを含む組成物の安定性を向上する方法 |
JP2015008707A (ja) * | 2013-07-02 | 2015-01-19 | 東洋紡株式会社 | 酵素の安定化方法 |
JP2015177790A (ja) * | 2014-02-27 | 2015-10-08 | キッコーマン株式会社 | アマドリアーゼ含有組成物の安定化方法、熱安定性が向上したアマドリアーゼ含有組成物及びこれを用いた糖化ヘモグロビン測定用組成物 |
JP2017527669A (ja) | 2014-09-09 | 2017-09-21 | ユニバーシティ・オブ・ワシントン | 官能性双性イオン性ポリマーおよび混合電荷ポリマー、関連するヒドロゲルならびにこれらの使用方法 |
JP6484742B1 (ja) | 2018-04-13 | 2019-03-13 | キッコーマン株式会社 | 新規メディエータ |
JP6484741B1 (ja) | 2018-04-13 | 2019-03-13 | キッコーマン株式会社 | 新規メディエータ |
JP2020163631A (ja) | 2019-03-28 | 2020-10-08 | 大日本印刷株式会社 | 樹脂フィルム、積層体及び包装製品 |
WO2021167011A1 (ja) * | 2020-02-21 | 2021-08-26 | キッコーマン株式会社 | 検体の状態を評価するためのデバイス、それを含むシステム、検体の状態を評価する方法及びそれに用いる乳酸デヒドロゲナーゼ |
-
2021
- 2021-09-29 JP JP2022554051A patent/JPWO2022071417A1/ja active Pending
- 2021-09-29 WO PCT/JP2021/035929 patent/WO2022071417A1/ja unknown
- 2021-09-29 US US18/246,060 patent/US20230365959A1/en active Pending
- 2021-09-29 KR KR1020237011749A patent/KR20230078697A/ko unknown
- 2021-09-29 EP EP21875715.1A patent/EP4223884A1/en active Pending
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58175498A (ja) * | 1982-03-26 | 1983-10-14 | メルク・パテント・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 液体中の物質の測定用試験系および試験方法 |
JPS61159164A (ja) * | 1984-09-21 | 1986-07-18 | ジヨナサン・エル・キ−ル | ミクロ化学発光アツセイシステム |
JPH01104172A (ja) * | 1987-10-16 | 1989-04-21 | Agency Of Ind Science & Technol | 酵素の安定化法 |
JPH034791A (ja) * | 1989-05-30 | 1991-01-10 | Kanebo Ltd | 酵素の安定化方法 |
JPH04271785A (ja) * | 1991-02-28 | 1992-09-28 | Kao Corp | 酵素固形製剤及びその製造方法 |
JP2000513940A (ja) * | 1996-07-03 | 2000-10-24 | モレキュラー バイオロジー リソーシス,インコーポレイテッド | 酵素の安定化のための方法および処方物 |
JPH1169973A (ja) * | 1997-08-29 | 1999-03-16 | Kao Corp | 酵素の安定化方法 |
JP2007129965A (ja) * | 2005-11-11 | 2007-05-31 | Toyobo Co Ltd | 可溶性補酵素結合型のグルコースデヒドロゲナーゼ(gdh)を含む組成物の熱安定性を向上する方法 |
JP2007163268A (ja) * | 2005-12-13 | 2007-06-28 | Canon Inc | 酵素電極 |
JP2008154573A (ja) * | 2006-03-31 | 2008-07-10 | Toyobo Co Ltd | 可溶性グルコースデヒドロゲナーゼ(gdh)を含む組成物の安定性を向上する方法 |
JP2009034095A (ja) * | 2007-07-06 | 2009-02-19 | Sanyo Chem Ind Ltd | タンパク質含有水溶液安定化剤、タンパク質含有水溶液の安定化方法及びタンパク質含有水溶液 |
JP2012099242A (ja) * | 2010-10-29 | 2012-05-24 | Toyota Motor Corp | 酵素燃料電池 |
JP2014018096A (ja) * | 2012-07-13 | 2014-02-03 | Kikkoman Corp | フラビン結合型グルコースデヒドロゲナーゼを含む組成物の安定性を向上する方法 |
JP2015008707A (ja) * | 2013-07-02 | 2015-01-19 | 東洋紡株式会社 | 酵素の安定化方法 |
JP2015177790A (ja) * | 2014-02-27 | 2015-10-08 | キッコーマン株式会社 | アマドリアーゼ含有組成物の安定化方法、熱安定性が向上したアマドリアーゼ含有組成物及びこれを用いた糖化ヘモグロビン測定用組成物 |
JP2017527669A (ja) | 2014-09-09 | 2017-09-21 | ユニバーシティ・オブ・ワシントン | 官能性双性イオン性ポリマーおよび混合電荷ポリマー、関連するヒドロゲルならびにこれらの使用方法 |
JP6484742B1 (ja) | 2018-04-13 | 2019-03-13 | キッコーマン株式会社 | 新規メディエータ |
JP6484741B1 (ja) | 2018-04-13 | 2019-03-13 | キッコーマン株式会社 | 新規メディエータ |
JP2020163631A (ja) | 2019-03-28 | 2020-10-08 | 大日本印刷株式会社 | 樹脂フィルム、積層体及び包装製品 |
WO2021167011A1 (ja) * | 2020-02-21 | 2021-08-26 | キッコーマン株式会社 | 検体の状態を評価するためのデバイス、それを含むシステム、検体の状態を評価する方法及びそれに用いる乳酸デヒドロゲナーゼ |
Non-Patent Citations (16)
Title |
---|
"12", NUCLEIC ACIDS RES., 1984, pages 9441 |
"Japanese Sepsis Clinical Practice Guidelines 2016", PNAS, vol. 112, no. 37, 15 September 2015 (2015-09-15), pages 11642 - 11647 |
AGRESTI ET AL.: "Ultrahigh-throughput screening in drop-based microfluidics for directed evolution", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 9, March 2010 (2010-03-01), pages 4004 - 4009, XP055206226, DOI: 10.1073/pnas.0910781107 |
BIOCHEM. J., vol. 258, 1989, pages 255 - 259 |
BIOCHEM., vol. 39, 2000, pages 3266 - 3275 |
CHEM. REV., vol. 105, no. 11, 2005, pages 4056 - 72 |
COMB CHEM HIGH THROUGHPUT SCREEN., vol. 11, no. 2, 2008, pages 127 - 34 |
CURR OPIN STRUCT BIOL, vol. 17, 2007, pages 474 - 80 |
DATABASE Uniprot 31 July 2019 (2019-07-31), ANONYMOUS: "Uncharacterized protein", XP009535714, retrieved from NCBI Database accession no. A0A4T0X365 * |
GENE, vol. 37, 1985, pages 73 |
METHODS ENZYMOL., vol. 154, no. 350, 1987, pages 1987 |
METHODS ENZYMOL., vol. 53, 1978, pages 238 - 56 |
NUCLEIC ACIDS RES, vol. 14, 1986, pages 9679 |
NUCLEIC ACIDS RES., vol. 13, 1985, pages 8765 |
PROC. NATL. ACID. SCI. U.S.A, vol. 82, 1985, pages 488 |
SPORTS PERFORMANCE RESEARCH, vol. 3, 2011, pages 31 - 48 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4108678A4 (en) * | 2020-02-21 | 2024-03-27 | Kikkoman Corporation | DEVICE FOR EVALUATION OF THE CONDITION OF A SAMPLE, SYSTEM COMPRISING SAME, METHOD FOR EVALUATION OF THE CONDITION OF A SAMPLE AND LACTATE DEHYDROGENASE USED FOR THIS PURPOSE |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022071417A1 (ja) | 2022-04-07 |
US20230365959A1 (en) | 2023-11-16 |
KR20230078697A (ko) | 2023-06-02 |
EP4223884A1 (en) | 2023-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5169991B2 (ja) | 改変型フラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼ | |
JP5176045B2 (ja) | 可溶性グルコースデヒドロゲナーゼ(gdh)を含む組成物の安定性を向上する方法 | |
WO2022071417A1 (ja) | フラビン依存性乳酸デヒドロゲナーゼを含む組成物の安定性を向上する方法 | |
JP4381369B2 (ja) | 可溶性補酵素結合型のグルコースデヒドロゲナーゼ(gdh)を含む組成物の熱安定性を向上する方法 | |
JP2022153244A (ja) | 熱安定性が向上した変異型グルコースデヒドロゲナーゼ及びその利用 | |
JP2010054503A (ja) | グルコース脱水素酵素を用いたグルコースの電気化学測定法 | |
JP6101011B2 (ja) | フラビン結合型グルコースデヒドロゲナーゼを含む組成物の安定性を向上する方法 | |
JP6652757B2 (ja) | フラビンアデニンジヌクレオチド依存型グルコース脱水素酵素活性を有する変異型タンパク質 | |
JP4381463B2 (ja) | 可溶性補酵素結合型のグルコースデヒドロゲナーゼ(gdh)を含む組成物の熱安定性を向上する方法 | |
JP6127496B2 (ja) | ジアホラーゼ | |
JP6440369B2 (ja) | フラビンアデニンジヌクレオチド依存型グルコース脱水素酵素活性を有するタンパク質 | |
WO2014119516A1 (ja) | ジアホラーゼ組成物 | |
JP5793841B2 (ja) | フラビンアデニンジヌクレオチド依存性グルコースデヒドロゲナーゼの比活性を向上する方法 | |
WO2019172400A1 (ja) | フラビンアデニンジヌクレオチドグルコース脱水素酵素とシトクロム分子との融合タンパク質 | |
WO2020116330A1 (ja) | グルコースデヒドロゲナーゼ | |
JP4770911B2 (ja) | 可溶性補酵素結合型のグルコースデヒドロゲナーゼ(gdh)を含む組成物の熱安定性を向上する方法 | |
JP2014143943A (ja) | Nad依存型グルコースデヒドロゲナーゼ組成物 | |
JP4591074B2 (ja) | 加熱処理を施した脱水素酵素 | |
JP2006034165A (ja) | Pqqgdh製造法 | |
JP6036826B2 (ja) | Nad依存型グルコースデヒドロゲナーゼおよびその製造方法 | |
JP2009189375A (ja) | 可溶性補酵素結合型のグルコースデヒドロゲナーゼ(gdh)を含む組成物の熱安定性を向上する方法 | |
JP2014097050A (ja) | ジアホラーゼ | |
JP2007129966A (ja) | グルコースデヒドロゲナーゼの熱安定性を向上する方法 | |
JP2006081407A (ja) | Pqq依存性グルコースデヒドロゲナーゼの製造方法 | |
WO2006068170A1 (ja) | グルコースデヒドロゲナーゼの熱安定性を向上させる方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21875715 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022554051 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20237011749 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021875715 Country of ref document: EP Effective date: 20230502 |